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ABSTRACT
The continued success of protein therapeutics has put a strain on industry's ability
to meet the large demand. Creating a more productive expression host for the
manufacture of these proteins is a potential solution. Although heterologous proteins are
frequently made in organisms as disparate as E. coli and bovines, the single-celled
organism S. cerevisiae has emerged as a well-qualified candidate due to its approachable
genetic and fermentation attributes as well as its ability to stably fold disulfide bonded
and multi domain proteins. Because S. cerevisiae screens for enhanced protein secretion
have traditionally utilized low-throughput and often plate-based methods, a high-
throughput, liquid phase assay could offer a real advantage in secretory selection.
In this thesis, yeast surface display is investigated as a potential proxy for
heterologous protein secretion. Although ultimately unsuitable as a screening proxy, the
surface display experiments did show a novel method of improving protein secretion by
co-expressing a more stably folded protein with the protein of interest. In these studies
the secretion of an scFv-Aga2p fusion was stimulated 10-fold by the concomitant surface
expression of BPTI. BPTI surface expression also stimulated the secretion of secreted
scFv three-fold suggesting a niche for protein coexpression as well as secretion by way of
Aga2p fusions.
A new screening method was developed that involves the capture of secreted
protein on the surface of the cell where it can be labeled and sorted by FACS. This new
method was verified to achieve thirty-five fold enrichment per pass for a three-fold
enhanced protein secretor making it easily suitable for screening. The new screening
methodology, the Cell Surface Secretion Assay (CeSSA), was also modeled and verified
with time course data that enabled optimization of sort parameters and predicted sort
outcomes based on user-derived selection parameters. The CeSSA was used to screen a
library of mutant yeast alpha mating factor leader sequences for improved secretion of
the scFv 4m5.3. The improved leaders imparted up to a twenty-fold improvement in
scFv secretion per cell and up to thirty-fold improvement after expression tuning. These
engineered leader sequences also conferred improved secretion on other scFv's and
proteins including whole IgG. Moreover, the leader sequence mutants give indications of
where the important residues in secretory leaders lie and the aberrations in protein traffic
that result in reduced secretion.
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Chapter 1: Introduction and Background
Recent advances in human genomics and proteomics have given science an
opportunity to better identify the causes and treatments for a vast array of diseases.
These advancements have been accompanied by an augmented ability to treat these
disorders using human proteins in place of traditional small molecules. Since the Elli
Lilly Corporation first made recombinant insulin in the early eighties, biotech companies
have staked their futures on their ability to solve ailments ranging from autoimmune
diseases, to metabolic disorders, to cancer using recombinant protein technology and the
industrial production of actual human proteins. Of course due to practical and ethical
considerations, it is impossible to make these proteins on any reasonable scale using
human hosts. Consequently, science and industry have turned to a variety of other
organisms to make protein for them. The work presented here utilizes the baker's yeast
Saccharomyces cerevisiae as an organism suitable for heterologous protein expression.
These studies include a novel method of improving the secretion of a single-chain
antibody using the co-expression of a more stable heterologous protein, the development
of a high-throughput assay capable of screening large libraries for mutations conferring
elevated levels of recombinant protein secretion, and finish with the development and
isolation of an improved protein leader sequence that, in combination with expression
tuning and additional host mutations, stimulates a thirty-fold increase in the production of
a single-chain antibody. The capability to produce more heterologous protein from an
expression host such as S. cerevisiae could help curb the current shortage in protein
therapeutic supply.
1.1 Recombinant Protein Production
Technological advances in drug discovery as well as the sequencing of the human
genome have provided a significant boost in the need for the production of therapeutic
proteins. In fact, it has been estimated that the worldwide protein therapeutic market will
reach $32 billion by 2005 and $71 billion by 2008 [1, 2] with 140 FDA approved
biologics and another 500 in clinical trials as of 2004 [3]. Most therapeutic protein
production is centered on the development of recombinant proteins (non-human and
human protein altered for improved efficacy) and recombinant monoclonal antibodies for
the treatment of cancer, neurological disorders, AIDS, and heart disease [4]. These
treatments either replace native proteins that are dysfunctional, poorly expressed, or
completely missing in a patient or interfere with processes involved in the progression of
a disease.
Almost as varied as the types of heterologous proteins being manufactured are the
types of expression hosts available for their production. Expression hosts range from
simple, prokaryotic organisms such as E. coli to large multi-system mammals and plants.
Each system has its requisite list of advantages and drawbacks typically involving an
inverse relationship between ease of production and protein fidelity. Microbial systems
involving organisms such as coli and S. cerevisiae tend to be highly fermentable,
relatively inexpensive to use, and genetically pliable yet are unsuitable for the production
of large, complex, and glycosylated proteins. Mammalian systems on the other hand can
produce complex proteins yet are difficult to generate, relatively expensive to maintain,
and create potential for toxic and infectious contaminants [5]. A summary of the benefits
and drawbacks of four groups of expression hosts is given in Table 1.1 (condensed from
Kamath (2005).)
Table 1.I Aspects of Heterologous Protein Production Hosts.
Microbial Mammalian Plants Animals
Expression System Bacteria, Animal and Plant cells, Transgenics
Yeast Human Transgenics
Cell Lines
Protein Levels High Medium High High
Cycle Time Short Short Seasonal Long
Complexity No Sometimes Yes Yes
(glycosylation)
Example Proteins mAb, Glycoproteins, mAb, vaccines, IgG, blood
enzymes vaccines enzymes proteins
At the present time, however, the demand for protein therapeutics far outpaces the
production capacity. Furthermore, issues with transgenic manufacturing cGMP, cell
culture intellectual property, expanded pharmaceutical indications, and high dosage
requirements threatens to worsen the problem [6]. Considering all of these potential
impediments to adequate market delivery, a more productive heterologous expression
vehicle would be beneficial in helping protein supply keep pace with demand.
The yeast Saccharomyces cerevisiae is an organism well-suited for heterologous
protein expression because of its eukaryotic secretory processing machinery, simple high-
density growth characteristics, short generation times, and easily alterable genetics.
However, although heterologous proteins secreted by S. cerevisiae are usually stably
folded and secreted into the supernatant, proteins are typically expressed at lower levels
relative to prokaryotic systems [7-11]. Improving the capacity of S. cerevisiae to secrete
recombinant protein could be a promising way of meeting market demand.
1.2 The S. cerevisiae Secretory Pathway
Although there are a variety of organisms suitable for heterologous protein
production, the yeast S. cerevisiae is ideal for production of simple, non-glycosylated
proteins because, unlike prokaryotic systems, it is capable of folding multi-domain
proteins including those that require disulfide bonds and then secreting the product into
the supernatant where it can be readily collected and purified. However, like prokaryotic
systems, S. cerevisiae is a single-celled organism able to be grown in dense-culture
fermentations utilizing simple media. S. cerevisiae and its relative P. pastoris are
currently used in the industrial production of insulin, Hepatitis B Surface Antigen,
Granulocyte Colony Stimulating Factor, Platelet-Derived Growth Factor, glucagon,
angiostatin, endostatin, and human serum albumin demonstrating its suitability for the
production of many important therapeutic proteins.
Eukaryotic secretory pathways are largely conserved albeit in different
complexities across phyla and rely on hierarchical progression of secreted protein
through distinct organelle environments. This traversal relies on both specific as well as
quite general protein/protein and protein/carbohydrate interactions. After transcription of
the expressed gene in the nucleus, the mRNA is exported into the cytosol where it begins
to be translated into protein. Signal sequences on the N-terminus of the nascent
polypeptide either directs the ribosomal complex to continue translation in the cytosol or
to migrate to a ribosomal receptor on the endoplasmic reticulum membrane to continue
translation concomitant with protein extrusion into the ER lumen [12]. Most of the
folding is performed in the ER lumen where folding chaperones assist in translocation,
the formation of disulfide bonds, N-linked glycosylation, and domain assembly [13-19].
The ER also possesses a quality control apparatus that ensures that only well-folded
protein is exported into later stages of the pathway as misfolded proteins are returned to
the cytosol for proteosomal degradation in a process termed ER associated degradation
(ERAD) [20-23]. This quality checkpoint is a distinct advantage of eukaryotic
expression over bacterial-based systems. After the protein has reached a stable
conformation in the ER, it is exported to the Golgi apparatus where it may be modified
by carbohydrate alterations or proteolysis. From the Golgi, the protein can either be
directed to the surface or to the vacuole, which serves as a degradation organelle among
other things (secretory pathway summarized in Figure 1.2.1) [24-29]. As we shall see,
improving recombinant protein secretion often means exerting influence over protein fate
at many of these points along the pathway.
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Figure 1.2.1 The Yeast Secretory Pathway. mRNA transcripts are translated on
ribosomes, and the nascent polypeptide is translocated into the endoplasmic reticulum.
Proteins are either folded correctly or retrotranslocated back into the cytosol for
degradation. Correctly folded proteins are trafficked to the Golgi via COPII vesicles
while ER resident proteins and misfolded secretory proteins are shuttled back in COPI
vesicles. From the late Golgi, protein can either be trafficked to the vacuole or the
surface.
1.2.1 Secretory Leader Sequence and ER Translocation
All secretion-directed protein must contain an N-terminal sequence that "informs"
the cell that the gene product is to be processed utilizing the secretory pathway. This
sequence is called the secretory leader or the "pre" sequence. Pre sequences can vary
widely in individual amino acid composition but do share some common themes among
eukaryotes. Typically, leader sequences contain a net positive charge between +1 and +3
toward their N-terminus. The charged sequence is then followed by a hydrophobic span,
and the leader ends with a more polar motif just before the non-polar signal-peptidase
(Sec 1 ip) cleavage site [12]. These motifs are required for proper processing and are,
therefore, sensitive to mutations affecting charge and hydrophobicity [30]. Although
translated protein must ultimately make its way to the ER, a couple of different pathways
for doing so are utilized in yeast, and the mechanism for ER entry is chiefly determined
by leader sequence [31]. In one pathway, proteins are completely translated before being
shuttled to the translocon complex on the ER membrane in a schema termed
posttranslational translocation. The yeast proteins alpha mating factor, the focus of
Chapter 4, and invertase are trafficked in this way [32, 33]. However, during cytosolic
translation nascent proteins exhibit exposed hydrophobic patches that are prone to
aggregation if not protected. The yeast protein Ssalp conceals hydrophobic motifs on the
polypeptide as well as chaperones the fully translated product to the translocon pore.
Chaperone activity requires ATP and is strongly enhanced by the presence of the ATPase
Ydjlp co-chaperone: a homolog to the DnaJ co-chaperones in coli [12, 34-37]. In fact it
is thought that Ydjlp activity is responsible for Ssalp dissociation that must occur before
translocation restarts [34, 38].
An alternative ER entry route involves simultaneous protein translocation and
translation in a process termed co-translational translocation. Although cerevisiae uses
both translocation pathways, mammalian cells use the co-translational translocation
pathway exclusively with the exception of the synthesis of some small peptides. Co-
translational translocation relies on the activity of the signal-recognition particle (SRP) to
direct the polypeptide/ribosome complex to a ribosome receptor (arguably p 180p, Sec6lp
itself, or a combination of both) near the translocon pore [12, 39, 40]. It is thought that
SRP binding stalls translation sufficiently to allow the complex to diffuse to the
Sec6lp/Sec63p complex where the SRP dissociates and translation continues [41].
Translational schemes are outlined in Figure 1.2.2.
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Figure 1.2.2 Translocation into the Endoplasmic Reticulum. Ssalp and the ATPase
stimulating Ydj 1 bind hydrophobic patches on post-translationally translocated protein.
The entire translation is fed through the Sec61p translocon pore through a process of
diffusion and ATP-driven BiP binding. Signal peptidase cleaves off the signal peptide
(A). In co-translational translocation, the signal recognition particle (SRP) binds the
signal sequence and guides the ribosomal complex to the SRP receptor where SRP
dissociates. Sec62 binds the signal sequence and guides it into the translocon pore
(Sec62 action not shown) where it is extruded by the translational activity of the
ribosome. BiP shields hydrophobic patches and signal peptidase cleaves the signal
peptide.
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The translocon pore exists as a complex of proteins that serves to engage the
polypeptide and then guide it into the ER lumen [42, 43]. Although the Sec61lp protein
has been shown to be the actual translocon pore [44, 45], Sec62p has also been shown to
be important as a potential signal sequence binder, and Sec63p may posses some DnaJ-
like co-chaperone activity in conjunction with the ER lumenal chaperone Kar2 [44, 46].
In post-translationally translocated proteins, the polypeptide is extruded by a "Brownian
ratchet" mechanism that relies on the random diffusion of the polypeptide into the lumen
where the binding of Kar2 inhibits retrograde motion [47]. This mechanism would
explain the importance of Kar2's association with the Sec63 subunit of the translocation
complex. In co-translational translocation, protein extrusion is powered by ribosomal
translation itself [48]. The signal peptide sequence is translocated as a hairpin loop and
then cleaved by signal peptidase (Sec 1lp), [12].
After the signal pre sequence is cleaved by signal peptidase, the remainder of the
leader, the "pro" region, helps direct the secretion of the protein through the rest of the
secretory pathway. Although a great many pro sequences exist in yeast, the most studied
by far is the pro region of the yeast alpha mating factor (MFalp). MFalp is a sixty-four
residue peptide that consists of three N-linked glycosylation sites provided by Asn-X-Thr
motifs. Although unglycosylated synthetic prepro leader sequences are able to direct the
secretion of heterologous protein, the glycosylation sites in MFa Ip are important to its
function as a secretory leader [49, 50]. Deletion of the glycosylation sites reduces
secretory competence and results in the intracellular accumulation of secretory protein
intermediate as unglycosylated alpha factor leader has been shown to be a substrate for
ERAD in vitro [51]. Furthermore, it appears that proper glycosylation of MFalp is
required before ER to Golgi transport in mating factor secretion [52]. Glycosylation sites
may influence protein folding by interacting with the calnexin/calreticulin glycoprotein
regulatory folding cycle [53]. Further studies with MFalp indicate that it is relatively
tolerant of in-frame amino acid insertions; however, in-frame deletions negatively impact
alpha factor secretion [52].
In addition to aspects of glycosylation, the pro region influences other stages of
secretory processing. ER translocation of insulin is dependent on the pro region even
with an intact pre sequence [54]. Furthermore, the pro sequence seems to be important
for the packaging of secretory protein into COPII vesicles for ER to Golgi transport.
Specifically, mutations in the 139, L42, and V52 residues significantly impact COPII
packaging in vitro and negatively impact MFalp processing in vivo [55]. Interestingly
synthetic prepro sequences have been designed that improve insulin precursor secretion
and are characterized by increased residence time in the ER suggesting that the pro
sequence may influence trafficking kinetics to effect a better folded protein [56]. Perhaps
one of the most important functions of the pro region is to stabilize the protein so that it is
not degraded. It has been shown that cleavage of the MFa p sequence leading the
secretion of an insulin-like protein influences whether the protein is directed to the
surface or to the vacuole. Thus, the presence of the pro region seems to have a stabilizing
effect on the protein allowing it to be directed to the surface. When the pro region is
cleaved, the protein is directed to the vacuole through one of many vacuolar sorting
proteins (VPS) [29].
1.2.2 Protein Folding in the ER
After translocation into the ER, the nascent protein interacts with a variety of
folding chaperones to ensure a well-folded final conformation. The most prominent
chaperone is the heat shock protein Kar2, the yeast homolog of mammalian
immunoglobulin binding protein (BiP). Kar2 contains a protein binding domain as well
as an ATPase domain. As the N-terminal ATP-binding domain cycles between ATP and
ADP, the substrate binding domain changes affinity for hydrophobic patches on unfolded
protein [13, 17, 18]. In this manner, the Kar2 protein can transiently interact with the
folding polypeptide keeping it from aggregating until the peptide is fully folded and the
Kar2 binding domains are hidden. In addition to its role in protein translocation and
folding, Kar2 is an intimate player in the unfolded protein response (UPR) that will be
discussed in detail in Chapter 2.
Another well-studied ER chaperone is the protein chiefly responsible for yeast's
ability to perform oxidative protein folding, protein disulfide isomerase (PDI). Like
Kar2, PDI is essential to yeast viability but also serves in promoting the formation and
isomerization of disulfide bonds [57]. PDI's oxidizing potential comes immediately from
the ER membrane protein Erolp but is thought to come ultimately from molecular
oxygen in a manner mediated by free flavin adenine dinucleotide (FAD) levels [14-16,
58]. As will be discussed later, overexpression of both Kar2 and PDI has been shown to
improve the secretion of recombinant protein [59-61].
Calnexin and calreticulin are two carbohydrate binding lectins that assist in
folding glycoproteins such as MFalp [62] as well as in protein degradation [51, 63].
Both chaperones bind to oligosaccharides containing terminal glucose residues on N-
linked carbohydrates which are transiently expressed during protein folding [64, 65].
This binding specificity allows them to work in concert with enzymes affecting
glycosylation to achieve a properly folded product. The enzyme mannosidase II cleaves
the terminal glucose on the carbohydrate causing calreticulin/calnexin to dissociate. This
release gives the protein a chance to fold properly. If the improper conformation is
reached, then glucosyltransferase, an enzyme with affinity for unfolded protein only,
reattaches the glucose subunit allowing the chaperone to bind it once again [19, 53]. In
this manner a nascent protein can make multiple attempts at correctly folding.
Carbohydrates on terminally misfolded proteins are cleaved in another place that causes
the protein to interact with the lectin ER-degradation enhancing mannosidase-like protein
(EDEM) that directs the protein to degradation in the proteosome [66, 67].
1.2.3 The Late Secretory Pathway
The two theories of protein exit from the ER involve the retention of misfolded or
resident ER protein in the face Golgi-directed bulk flow or the active sorting of proteins
into COPII vesicles destined for export. It seems that there are data to support both
theories [68] [55]. Protein can progress through the Golgi cisternae in both anterograde
and retrograde directions. ER resident protein that has escaped into the Golgi is retrieved
via its HDEL (KDEL in mammalian cells) C-terminal retrieval sequence and is packed
into COPI vesicles to be shuttled back to the ER. It has been shown that misfolded
proteins in the Golgi can be recycled back to the ER via BiP's retrieval sequence to be
refolded [69, 70]. This feature is important as the Golgi contains no folding chaperones
of its own. The Golgi body is also the last quality control point as the cell decides
whether to send protein to the surface or to the vacuole for degradation. The sorting
receptors responsible for this decision are the family of vacuolar sorting proteins (VPS).
The tendency for a protein to be sorted to the vacuole by a VPS appears to be dependent
on protein stability as well as a positive sorting signal (particularly for hydrolases that are
normally vacuole resident proteins) [24]. In addition to surface directed traffic, proteins
can be sorted to the vacuole via clathrin-coated pits [25], through an endosomal
intermediate [26-28] or to a late endosome/multi-vesicular body [24]. It has been shown
that for some yeast proteins ubiquination is required for vacuole sorting by way of an
endosomal intermediate [71]. It has also been shown that insulin-like protein can be
sorted to the vacuole by way of the endosome through interaction with VPS receptors
[29].
1.3 Protein Trafficking and Secretory Bottlenecks
With a clear understanding of secretory pathway fundamentals and trafficking
steps, more information about secretory impediments and trafficking rates can be derived.
We can get a feeling of the size of the flux through the translational, secretory, and
degradation arms of the secretory pathway by looking at pulse-chase experiments. When
radioactive alpha-amylase is chased through the secretory pathway, one finds that only
two percent of the radioactive protein that had been synthesized during the pulse is
ultimately secreted. Meanwhile, the amount of intracellularly retained radioactive protein
gradually declines from 50% of the original retention at ten minutes into the chase down
to 23% thirty minutes into the chase during which time no increase in extracellular
protein is seen [72]. These data suggest that there are high levels of protein degradation
occurring in the cell that are limiting the amount of protein able to reach the surface
(Figure 1.3.1A). This degradation could be occurring in the ER or vacuole and may be
due to protein mistrafficking or protein instability and misfolding.
Protein molecular weights as well as glycosylation patterns in cell lysate are
indicative of the progress the protein has made through the secretory pathway. For an
example where lysate is used to measure rates of protein maturation, one can look at
Heim's work examining the processing of radioactively labeled alpha mating factor
prepro led human insulin-like growth factor in a yeast strain deficient in vacuolar
proteases [73]. Thirty seconds after the radioactive pulse, high molecular weight species
of IGFI begin to appear in the intracellular lysate. These species are prepro IGFI
representing singly, doubly, and triply glycosylated forms proven by their sensitivity to
the deglycosylating enzyme EndoH. It is important to note that no unglycosylated
MFapp IGFI appears in the lysate at any time point during the chase suggesting that
translation, translocation, and glycosylation rates are too fast to allow significant
accumulation of MFapp IGFI in an unglycosylated form. At the two-minute time point,
significant amounts of lower molecular weight unglycosylated IGFI begin to accumulate
intracellularly. This form is Kex2 cleaved mature IGFI that has traversed at least as far
as the late Golgi. However, despite the early accumulation of mature protein, it is not
until thirty minutes after the pulse that protein begins to appear in the supernatant. From
these data it is apparent that MFapp IGFI is efficiently translocated, glycosylated and
folded. It is also clear that ER export and trafficking to the late Golgi is also relatively
rapid. However, once the protein has reached its mature form, a processing bottleneck
keeps it inside the cell and out of the supernatant. From what is known about post-Golgi
secretory trafficking, one might hypothesize that mature IGFI is being routed to the
vacuole where a pep4 deletion in the host slows its degradation instead of the surface. A
schematic of IGFI trafficking fitting this hypothesis is given in Figure 1.3.1B. To
improve the secretion of IGFI in yeast cells, one would have to find a way to reroute
mature insulin to the surface. Indeed, Zhang and colleagues did exactly that when they
found that deletions in the late Golgi localized vacuolar sorting proteins VPS8, 35, 13, 4,
and 6 caused MFapp led IGFI precursor to be diverted to the surface instead of the
vacuole (2001). By removing a rate-limiting bottleneck (a counterproductive sorting
step), the rate of IGFI secretion was enhanced.
Other studies have found that vacuolar degradation is important in trafficking of
other proteins. The trafficking of destabilized mutants of BPTI are unaffected by
mutations in ERAD-associated proteins [74] but are instead trafficked to the vacuole
[75]. From these results it is apparent that some protein is able to escape the primary
quality control checkpoint in the ER only to be sorted from the Golgi for vacuolar
degradation. Proteins may be sorted due to instabilities caused by Golgi processing.
Movement through the Golgi body is concomitant with protein concentration, organelle
acidification, and extensive alteration in glycosylation patterns [76, 77]. Perhaps these
modifications destabilize the protein and cause it to fail quality control in the late Golgi.
If this scenario is accurate, then perhaps altering genes governing organelle acidification,
concentrative protein sorting, or glycosylation would be another method of improving
BPTI or IGFI secretion.
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Figure 1.3.1 Secretory Bottlenecks. Pulse-chase experiments of a-amylase secretion
indicate that only -2% of synthesized protein is secreted suggesting that the vast majority
is degraded by ERAD or the vacuole (A). The bar width indicates the size of protein
flux. A more detailed pulse-chase of MFapp IGFI indicates that vacuole directed protein
trafficking causes a reduction in secretion of IGFI (black lines); furthermore, yeast
mutations compromising the vacuolar sorting proteins responsible for this step as well as
a deletion of Kex2 successfully reroute insulin to the surface (red lines, B).
It should be pointed out at this point that different proteins can have different
secretory bottlenecks, and there is sometimes more than one significant bottleneck in a
pathway for a single protein. For example, is seems scFv secretion rates are limited by
folding in the ER. Overexpression of proteins involved in ER folding, PDI and Kar2,
increase the amount of scFv secreted into the supernatant suggesting that formation of
disulfide bonds as well as aggregation or translocation issues may impose secretory
bottlenecks [61]. On the other hand, mRNA transcripts limit the secretory processing of
wild-type BPTI. Consequently, BPTI secretion is improved by increasing the copy
number of the gene [78]. It is these types of studies that highlight the nuances involved
in improving heterologous protein secretion. Furthermore, these studies also illustrate the
need for a comprehensive method of examining all of the potential bottlenecks for a
protein of interest in order to relieve the secretory bottleneck most pertinent to the
protein.
1.4 Gene Expression in S. cerevisiae
Genes to be expressed in S. cerevisiae are typically introduced into yeast on low-
copy (1 to 3 copies per cell) centromeric (CEN) plasmids, high copy 2pm plasmids, or
through integration into the chromosome via homologous recombination. The studies
outlined here mostly utilize CEN plasmids as well as a few examples of integration.
Heterologous genes are usually expressed from a strong promoter in order to maximize
the amount of mRNA that can be translated into protein. Promoters such as the
cytochrome c (CYC) or glycerol phosphate dehydrogenase (GPD) promoters can be
constitutively activated, and other promoters can be specifically activated usually through
the introduction of a nutrient such as copper or galactose into the media. The promoter
used for these studies is the Gall-10 promoter normally used for galactose metabolism.
The Gall-10 promoter governs the divergent transcription of two genes (Gall and
Gall0). Transcription is stimulated by the binding of Gal4p to the upstream activating
sequence inside the Gal promoter. However, under conditions where galactose is not the
primary carbon source, Gal80p inhibits Gal4p activity. When galactose is added to the
culture, it activates the transcription of Gal3p that in turn binds and sequesters Gal80p
causing it to dissociate from Gal4p leaving Gal4p to activate the transcription of the Gall
and Gall0O gene products. Transcription of Gal3p is turned off in the presence of glucose.
This regulatory loop enables a gene inserted in place of the Gall gene to be strongly
transcribed when galactose is added to the media but be suppressed when grown in
another carbon source particularly glucose (Figure 1.4) [79]. In fact cell growth in
galactose stimulates the production of mRNA transcribed from the Gall-10 promoter
about five hundred fold over transcriptional levels when grown in raffinose [80].
Glucose I
Gal UAS
Gal UAS
Figure 1.4 The Gall-10 Regulatory Operon. Gal80p causes a repression in gene
expression by binding the transcription activating protein Gal4p. Galactose relieves this
repression by stimulating the production of Gal3p, which binds Gal80p leaving Gal4p
free to stimulate transcription of a downstream gene.
1.5 A Directed Evolution Approach
Many approaches to improving recombinant protein secretion in yeast have been
attempted with some degree of success. Most of these successes rely on the perturbation
of a secretory pathway participant through overexpression [59-61, 72] or deletion [29, 81,
82]. However, it is clear from previous work that large libraries are needed in order to
robustly isolate higher secreting clones. Moreover, different types of secreted proteins
require the modification of different secretory pathway participants. Proteins in the ER,
Golgi, transport vesicles, and nucleus have all been found to improve protein secretion
when modified (Table 1.II). A screening philosophy that embraces and even integrates
the large diversity of potential solutions would be ideal for improving heterologous
protein secretion. With these themes in mind, a model approach to secretory maturation
i
Galactose "C
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is directed evolution. Directed evolution, frequently utilized in protein engineering, relies
on the generation of diversity from a previously homologous population followed by
iterative rounds of selection in order to isolate clones that are best fit for the selection
criteria. As applied to secretory improvement, directed evolution would mean the
generation of a library of host or protein mutants and then the selection of mutants that
exhibit elevated levels of secretion. This process could be performed over and over even
employing different types of libraries until the best, or at least a sufficient, solution to the
secretory problem is found (Figure 1.5).
0o
Original Strain
°°
0 I
Introduction of
Diversity
Selection
Figure 1.5 Directed Evolution of a Diversified Library. A homologous population of
cells undergoes diversification through the introduction of host or protein mutations. In
this case, the higher secretors are selected and the process is repeated until the library has
enriched sufficiently. This method may incorporate many rounds of selection utilizing
different types of libraries.
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lones
1.6 Flow Cytometry and FACS
One of the problems associated with isolating mutations for secretion is the rather
unwieldiness of the screening process. In order to screen large libraries, time consuming
and inefficient assays such as Western blots and halo assays have been employed. These
assays frequently require the screens to be performed on plates, which is an environment
far removed from the fermentation conditions experienced in industrial production.
Furthermore, the library size becomes limited to the amount of clones one is able to put
into the assay. Table 1.II summarizes a few previous strategies for improving
heterologous protein secretion in yeast and outlines the methods used as well as the
results.
Table 1.II Selected Studies on Improving Heterologous Protein Secretion in Yeast
4x to 10x
4x
5x to 50x
Redirected from
total degradation
3x in K. lactis
Overexpression of PDI,
BiP (ER)
Overexpression of Sso 1
(transport vesicles)
Deletion of PMR1
(Golgi)
Deletion of VPS genes
(Golgi)
Deletion of SELl
(unknown)
Rational
Suppression
Screen
Suppression
Screen
Western blot
Plate
screening
As can be inferred from Table 1.II, the ability to screen large numbers of clones in
a high throughput manner would be a real advantage to the field. A solution to that
problem is to utilize fluorescence activated cell sorting (FACS) as a selection tool. Flow
cytometry relies on the differentiation of phenotype through the association of fluorescent
labels and cells. Cells are labeled with a fluorescent dye and immersed in droplets of
scFv
a-amylase
Various
Proinsulin
Human
Growth
Hormone
[61]
[72]
[81]
[29]
[82]
saline solution that have been charged by a piezoelectric tip on a vibrating nozzle. A laser
excites the cell-associated fluorophores, and the resulting photons are absorbed by a
series of detectors each calibrated for a specific wavelength of light. The cell's
fluorescent properties are detected and analyzed, and cells meeting the fluorescence
criteria are kept by way of electromagnetic deflection into a sample collection tube. Cells
that do not meet the criteria pass into a waste stream (Figure 1.6). This method is very
efficient relative to traditional screening methods in that it can analyze and sort up to one
hundred million cells an hour. Consequently, a couple of seconds of flow time can
reproduce a screen that might take months using other techniques. Furthermore, cell
fluorescence is quantifiable thus presenting a numerical relationship between clone and
phenotype.
Detector 1
Droplet/Cell I
Laser
0
Waste
Figure 1.6 Fluorescence Activated Cell Sorting. Charged cells are dispersed in
droplets then travel through a laser that excites cell-associated fluorophores. The
resulting photons are detected and analyzed such that a comparison between the cellular
properties and the sort criteria can be made. Cells meeting the criteria are sorted by a
deflection plate into a sample collection tube. Other cells are discarded.
1.7 Thesis Overview
Having established the need for a high-throughput method to select S. cerevisiae
hosts with enhanced recombinant protein secretion capability, it is the goal of this thesis
to devise and validate a flow cytometric method for selection and to successfully
demonstrate a directed evolutionary approach resulting in the generation of a hyper-
Selected
secreting clone or construct. In the second chapter, yeast surface display is explored as a
potential screening proxy. Furthermore, experiments will show that co-expressing two
heterologous proteins simultaneously improves the expression of both and results in the
dramatic secretory improvement of a single-chain antibody. Chapter 3 describes a yeast
screening assay centered on using actual secreted protein rather than protein fusions to
generate a link between secretory phenotype and host genotype. This method will be
validated and modeled so that it may be efficiently used for the selection of mutagenic
libraries. Chapter 4 will apply this screening system to the directed evolution of a
secretory leader peptide and demonstrate that this approach can be a successful way to
generate hyper-secreting constructs from a large library. The isolated leader sequences
will be used alone and in combination with other strategies to enhance the secretion of a
variety of recombinant proteins.
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Chapter 2: Yeast Surface Display and Simultaneous
Expression
2.1 Introduction
A screening proxy for protein secretion selections should take full advantage of
the yeast secretory pathway just as a true secreted protein would. In yeast, secretion-
directed proteins are translocated into the ER through the Sec61/Sec63 complex.
Translocation can be performed either post-translationally or co-translationally although
the latter relies on the interaction with the signal recognition particle (SRP) for shuttling
to the ER membrane and is used exclusively in mammalian cells [1-3]. After
translocation into the ER lumen, the nascent proteins interact with a variety of folding
chaperones that assist the protein in reaching a state suitable for export from the ER. The
most prominent of the folding chaperones is immunoglobulin binding protein (BiP, Kar2
in yeast) that not only inhibits protein aggregation but is also thought to assist in protein
translocation as well as the unfolded protein response (UPR). In addition chaperones
such as protein disulfide isomerase (PDI) participate in the formation of disulfide bonds
between cystein residues, and carbohydrate-binding lectins such as calnexin and
calreticulin are also used to ensure proper folding and glycosylation [4]. Historically,
overexpression of these proteins has been a productive method for improving the
secretion of some heterologous proteins such as single-chain antibodies (scFv) and
human lysozyme [5-7]. One of the attractive features of expression in yeast is that they
have their own internalized protein quality control. Protein that does not fold properly is
retro-translocated through the Sec61 pore, ubiquitinated by an E3 ubiquitin ligase, and
degraded by a 26S proteosome. This collective process is termed ER associated
degradation (ERAD) and is intricately related to the secretory health of the cell [8-10].
Secretory stress is often concomitant with high-level expression of recombinant
protein and triggers a mechanism known as the unfolded protein response (UPR) [11,
12]. This response is mediated through the ER membrane localized kinase inositol
requiring protein (IRE1). Although normally associated with BiP, IRE1 homodimerizes
and transphosphorylates when BiP is recruited away by high levels of unfolded protein.
IRE1 phosphorylation activates the endonucleolytic activity of the dimer causing it to
splice an intron out of the mRNA for the transcription factor Hac 1. Spliced Hac 1 is then
translated and goes on to stimulate the transcription of numerous genes involved in
helping the cell cope with secretory stress (Figure 2.1.1) [13]. These upregulated genes
code for proteins involved in membrane proliferation, protein folding, and protein
degradation [10, 14, 15]. UPR manipulation has even been used to increase the secretion
of some heterologous proteins [16].
Hacl mRNA
Genes for Coping
with Secretory Stress
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ER lumen
Figure 2.1.1-The Yeast Unfolded Protein Response. The UPR is instigated by the
endonuclease activity of the ER membrane protein IRE 1. IRE1 is normally associated
with the soluble ER protein BiP until BiP is recruited away to help stabilize high levels of
unfolded protein. This migration allows IRE to homodimerize and transphosphorylate
stimulating its endonucleolytic activity. The activated IRE1 dimer splices an intron out
of Hac 1 mRNA allowing active Hac Ip transcription factor to be translated. Hac lp then
goes on to stimulate the expression of a variety of genes involved in helping the cell cope
with ER stress.
Proteins that have passed ER quality control are packaged into COPII vesicles and
shuttled to the Golgi. The Golgi serves as the final protein quality checkpoint as well as a
location for further protein modifications that typically consist of glycosylation and
peptidase activity. It has also been shown that improperly folded proteins can be
retrieved from the Golgi and transported back to the ER. This late quality control may be
mediated by BiP acting as an adapter complexing with both the unfolded protein and the
KDEL ER-retention receptor [17-19]. Vacuole targeted and misfolded proteins are sorted
to the vacuole by a family of vacuolar sorting proteins (VPS) [20]. Proteins can be sorted
directly to the vacuole via clathrin-coated vesicles in a pathway termed the alkaline
1 
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phosphatase pathway (ALP) [21], through an endosomal intermediate [22-24], or directly
to a multi-vesicular body (MVB) in the CPY pathway [25]. In addition proteins can be
sorted directly from the trans-Golgi to the surface. The factors that govern this sorting
decision are still being worked out, but it appears that a positive sorting signal on the
secreted proteins as well as varying levels of protein ubiquitination may play a role [25,
26]. Some heterologous proteins such as insulin are sorted through the endosomal
pathway, and deletions of various VPS's involved in endosomal sorting have increased
surface directed traffic of this protein [27]. In addition, it has been shown that protein
stability may contribute to the propensity of a protein to be sorted to the vacuole.
It is clear that cells process different heterologous proteins in different ways. In
the following experiments, we dissect the trafficking of two different, simultaneously
expressed heterologous proteins: bovine pancreatic trypsin inhibitor, which can be
secreted at levels up to 180 mg/L [28] and D1.3, which is a member of a class of proteins
termed single-chain antibodies (scFv) and are relatively poorly secreted at 10-20 mg/L
[7]. These studies show that co-expression has strong effects on protein trafficking
particularly in the late secretory pathway. It appears that BPTI and D 1.3 compete for the
same retentive sorting protein resulting in a significant improvement in the secretion of
the less stable D1.3 and a more subtle improvement in the surface expression of BPTI.
These results demonstrate a novel method for improving the secretion of a heterologous
protein with a potential improvement anywhere from three to ten-fold depending on the
protein and the construct.
2.2 Experimental Protocol
2.2.1 Strains, Plasmids, and Growth
pDl.3s and pBPTIs, the low-copy CEN plasmids of secreted D1.3 and BPTI,
consist of the GAL1 promoter, synthetic prepro signal peptide, D1.3 or BPTI, the c-myc
epitope tag, and the GAL4 terminator sequence (plasmid diagrams in Appendix 2.1). The
surface display plasmids pD 1.3Cmd and pBPTICmd are similar to the secreted forms but
contain the agglutinin-2 gene between the c-myc tag and GAL4 terminator. An
additional BPTI display plasmid, pBPTICfd, had a flag tag substituted for the c-myc tag
in pBPTICmd. The doxycycline titratable Hacl spliced variant plasmid pCYHi-1 was
made by amplifying the Hacli gene from pJC-835 [13] by PCR with primers containing
flanking BamHI and NotI restriction sites (primer sequences given in Appendix 2.6) and
then subcloning the PCR product into pCM189 (ATCC) with a BamHI/NotI digest
(Appendix 2.3).
2.2.2 Strain Descriptions
EBY100 (Invitrogen, Chicago IL) was the strain used for secretion of BPTI and
D1.3. The D1.3 and BPTI integrated surface display strains JARD1.3 and JARBPTI
were made by amplifying D1.3 from pD1.3Cmd or pBPTImd (Appendix 2.2) by PCR
with the 5' primer carrying -45 bp homology to the URA3 gene, and the 3' primer
containing a 48bp linker. In addition the G418 resistance gene was amplified from
KanMX [29] using a 5' primer homologous to the linker described above and a 3' primer
homologous to URA3. Simultaneous lithium acetate transformation [30] of 10 gg of
these two PCR products into EBY100 stimulates a recombination event that results in the
G418R marked integration of either D1.3 or BPTI into the host URA3 gene locus.
Transformants were selected on plates containing 200 glg/mL Geneticin (GibcoBRL,
Chicago, IL). The co-expressing strain JAR2DB was constructed by co-transforming the
D1.3/G418 integration pair with a BPTICfd/Zeocin resistance integration pair. The
Zeocin gene was amplified from picZt (Invitrogen, Chicago, IL) using a method like the
one described above.
To ensure that differences between expression in the single displaying and co-
displaying D1.3 integrations were not due to differences in gene integration, a PCR-based
method for checking integration copy number was used. Genomic DNA from 5x10 7 cells
was isolated using a Zymoprep Yeast Plasmid Miniprep Kit (Zymo Research, Orange,
CA). 1.2 gL of DNA dilutions from 1:1 to 1:1000 were used as template in a PCR
reaction utilizing primers homologous to the D1.3 integration as well as another pair of
primers homologous to the glyceraldehyde 3-phosphate dehydrogenase (GPD) gene as an
amplification control. The PCR products were separated by electrophoresis and stained
with 1:5000 TAE dilution of SYBR Gold (Invitrogen). The product bands were
quantified using a Fluor-S Multilmager with Quantity One 4.2.0 software (Bio-Rad,
Hercules, CA). The bands were analyzed for template concentrations yielding a linear
range in product signal versus template concentration. The proportion of D 1.3 signal to
GPD signal for JARD1.3 and JARDB in this range was the same indicating that there
were equal numbers of integrations in the two strains. A list of plasmids and strains is
given in Table 2.2.I
Table 2.2.I: Plasmids and strains described in this chapter
Name Description Source/Reference
Strains
EBY100 mat a, trpl, leu2deltal, pep4::HIS3 prbldel, URA3::galactose promoted Agal Shusta et. al., 1999
JARD1.3 EBY100 with integrated, surface-displayed, c-myc tagged D1.3 This work
JARBPTI EBY100 with integrated, surface-displayed, c-myc tagged BPTI This work
JAR2DB EBY100 with integrated, surface-displayed, c-myc tagged D1.3 and flag tagged BPTI This work
Plasmids
pDI.3s CEN plasmid containing secreted c-myc tagged D1.3 This work
pBPTIs CEN plasmid containing secreted c-myc tagged BPTI This work
pDl.3md CEN plasmid containing surface-displayed, c-myc tagged DI.3 This work
pBPTImd CEN plasmid containing surface-displayed, c-myc tagged BPTI This work
pBPTIfd CEN plasmid containing surface-displayed, flag tagged BPTI This work
pJC-835 CEN plasmid containing constitutively active form of Hacl i  Cox and Walter, 1996
pCYHi-1 CEN plasmid containing Haci promoted from doxycycline repressible CYC promoter This work
pCM189 CEN shuttle vector containing doxycycline repressible CYC promoter ATCC
pPDI CEN plasmid with galactose-promoted PDI LaMantia et. al., 1993
pgalKar2 CEN plasmid with galactose promoted Kar2 (BiP) Robinson et. al., 1996
pGPDKar2 CEN plasmid with GPD promoted Kar2 (BiP) Robinson et. al., 1996
pRS316 CEN shuttle vector bearing Ura3 nutritional marker New England BioLabs
pKTO48 CEN plasmid containing UPR activated GFP reporter gene Travers et. al., 2000
picZa CEN shuttle vector containing Zeocin resistance gene Invitrogen
pFA6-kanMX4 CEN shuttle vector containing G418 resistance gene Wach et. al., 1994c
2.2.3 Western Blot of Secreted Protein
D.13 or BPTI transformed cells were grown overnight in SD-CAA and then
induced by dilution into fresh SG-CAA to an OD of 0.5. After three days of growth, 21
gL of supernatant was loaded onto a SDS 12%-Tris-Glycine polyacrylamide gel
(Invitrogen). The protein was then transferred onto nitrocellulose then blocked and
stained with 1 gg/mL chicken anti-myc antibody followed by (1:1000) goat anti-chicken
HRP-conjugated antibody. The blot was developed with 1.5 mL of SuperSignal ELISA
Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL) and imaged on a Fluor-S
MultilImager. The Westerns involving secreted surface displayed protein were done
similarly but with (1:1000) dilution 9e 10 anti-c-myc antibody (Covance, Denver, PA)
and (1:1000) goat anti-mouse HRP conjugate. Blot densities were determined using
Fluor-S Multilmager Quantity One 4.2.0 software.
2.2.4 Flow Cytometry
JARD1.3 and JARBPTI were grown in 5 mL YPD overnight at 300 C and then
induced by dilution into YPG to an initial OD600 of 0.5. Growth continued overnight and
then 0.2 0D 600 of cells were taken and labeled for surface display with 20 jgg/mL chicken
anti-c-myc antibody followed by 40 pgg/mL Alexa488-conjugated goat anti-chicken
antibody (Invitrogen). Analysis was carried out on a Coulter Epics XL flow cytometer
(Coulter, Miami Lakes, FL).
JARDB was transformed with pKT-048 and pRS316, an empty nutritional
marker. Cells were grown overnight in SD-CAA and then induced in YPG as described
above. After overnight induction, 0.2 OD600 of cells were labeled with 80gg/mL anti-flag
M2 antibody (Sigma, St. Louis, MO) and 3 ag/mL biotinylated lysozyme (Sigma). The
cells were then washed and labeled with 10 ýtg/mL allophycocyanin-conjugated
streptavidin (Invitrogen) and 40 jgg/mL phycoerythrin-conjugated goat anti-mouse
antibody (Invitrogen). Analysis was performed on a FACSCalibur Flow Cytometer (BD
Biosciences, San Jose, CA). The data were analyzed on Cytomation Summit MoFlo
Acquisition Software (Cytomation, Fort Collins, CO). Some of the integrations were
unstable as tested by reversion to antibiotic sensitivity, so some of the cells only
displayed one protein on their surface. Gates were drawn around single expressing cells
as well as dual protein expressing cells (three gates total) and the mean fluorescence was
extracted from the data for each of these gates. The UPR fluorescence was also gathered
from these data.
To study the effects of UPR titration, pCYHi-1 and pKT048 were transformed
into JAR2DB. Cells were inoculated into SD-CAA with 100 gg/mL doxycycline hyclate
(Sigma) in order to repress expression of Hacl . Cells were induced by passaging 2.5
OD600 of cells into 5 mL YPG containing 0 to 10 jlg/mL doxycycline. Cells were grown
overnight and 0.2 OD600 were removed and stained with either 20 gLg/mL biotin-trypsin or
3 gg/mL biotin-lysozyme. Both cells received 10 Cgg/mL streptavidin-PE (Invitrogen) as
a secondary cytometric reagent.
Cells co-expressing folding chaperones and additional agglutinin-1 were grown in
SD-CAA and induced in YPG as described above. Similar labeling methods were used
for surface expression analysis. For detailed surface display protocols, see Appendix 1.2.
2.2.5 Fluorescence Microscopy
Co-expressing JAR2DB and single-expressing JARD1.3 were inoculated into
YPD, grown overnight, and then induced to an OD600 of 0.5 in 5 mL YPG, and then
grown overnight. Cells were fixed with formaldehyde and digested with zymolase
diluted in PBST. 0.5 OD 600 of cells were incubated in 10 gg/mL chicken anti-c-myc
antibody as well as 20 gg/mL 13D 11 anti-vacuole membrane antibody. After washing,
cells were incubated in 40 .g/mL Alexa488-conjugated goat anti-chicken antibody, 10
gg/mL goat anti-mouse PE, and 1 mg/mL Hoechst dye. After incubation and washing the
cells were added to L-polylysine coated, acid washed slides, and analyzed on a Zeiss
Axiovert 100TV Deconvolution Fluorescence Microscope (Zeiss, Dublin, CA). Images
were taken with a Series 300 cooled CCD camera (Photometrics, Tucson, AZ) and
manipulated using DeltaVision softWoRx software (Applied Precision, Issaquah, WA).
Detailed microscopy protocols can be found in Appendix 1.3.
2.2.6 Secreted D1.3 Functionality
The fidelity of the secreted surface displayed D1.3 was tested by labeling 0.2
OD 600 of cells conjugated to lysozyme via a biotin-PEG, avidin, biotinylated lysozyme
cell surface construct with 500 gL of supernatant and labeling with an anti-myc and goat
anti-chicken antibody as described above. Cells were then analyzed by surface display.
Cells were also incubated in supernatant containing 4m5.3 as a negative control. More
information on the cell surface lysozyme labeling can be found in Chapter 3 and
Appendix 1.4.
2.2.7 Co-secretion and Surface Display
The strains BJ5464a and JAR200 were transformed with flag-tagged D1.3, synthetic
prepro directed 4m5.3, alphaprepro 8 directed 4m5.3 (Chapter 4), or synthetic prepro
directed IL-2 (Q126R). JAR200 cells were transformed with a copy of pBPTImycflag.
Cells were grown overnight in SD-CAA and then induced for 24 hours in YPG. A
Western blot was performed as described above using 275 ng/mL anti-flag HRP. Cells
co-secreting D1.3 were analyzed for BPTI surface display using techniques outlined
above.
2.3 Results
2.3.1 Yeast Surface Display and Secretion
Because the very nature of secretion dictates the separation of protein and cell, a
screenable proxy for secretion is needed. Yeast surface display could serve as such a
proxy. In yeast surface display, surface directed proteins are expressed as fusions to the
yeast mating adhesion protein agglutinin-2. Agglutinin-2 forms disulfide bonds with the
cell wall protein agglutinin-1 allowing the entire construct to be expressed on the cell
surface where the protein can be labeled with fluorescent dyes and sorted by flow
cytometry (Figure 2.3.1).
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Figure 2.3.1-Surface Display Construct. The epitope tagged protein of interest to be
displayed (POI) is fused to the yeast agglutinin 2 (Aga2) protein and co-expressed with
agglutinin 1 (Agal). The Aga2 covalently associates with Agal via two disulfide bonds
formed in the ER, and the entire construct is displayed on the yeast cell surface through
the GPI-anchor present on Agal. The surface displayed protein and its epitope tags can
be labeled with fluorescently tagged antibodies and analyzed by flow cytometry.
There has been evidence to suggest that yeast surface display can serve as an
effective secretion proxy under certain conditions [31]. To illustrate the linkage between
surface display and secretion for two proteins with different thermodynamic stabilities,
the single-chain antibody variable fragment (scFv) D1.3 and the small protein bovine
pancreatic trypsin inhibitor (BPTI) were expressed solubly and as Aga2 linkages in S.
cerevisiae. Soluble expression shows that BPTI is secreted approximately five-fold
better on a molar basis than D1.3 when expressed from CEN-plasmids (Figure 2.3.2, A).
Chromosomally integrated Aga2 fusions of BPTI showed similarly enhanced (about 3.5-
fold) levels of surface display compared to surface displayed D1.3 (Figure 2.3.2, B).
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Figure 2.3.2-Correlation between Secretion and Surface Display. The yeast
secretory pathway processes BPTI more efficiently than D1.3 as shown by higher levels
of BPTI present in the supernatant of secreting cells (A). BPTI is also surface displayed
at higher levels than D1.3 as shown by flow cytometric assay (B).
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The ability of surface display to accurately predict soluble expression levels from
traditional secretion constructs in addition to the study cited above relating
thermostability and surface display suggest that surface expression could provide a
suitable proxy for secretion. Surface expressed constructs traverse the same secretory
pathway as supernatant directed traffic and because the agglutinins are native yeast
proteins, it is reasonable to assume that the additional impact on the secretory system
imparted by the fusions is minimal. Lastly, labeling the surface displayed protein with
lysozyme or trypsin guarantees that the construct is well-folded and functional.
2.3.2 Co-expression of D1.3 and BPTI
Secretory improvements have historically been specific to the protein that is being
secreted. As a general rule, it is often difficult to extrapolate host mutations or culture
conditions that have been successful for one protein into a strategy that is useful for other
proteins. In order to find mutations that might be beneficial for a wide span of secreted
proteins, surface directed BPTI and D 1.3 were co-expressed in the same cell and
screened simultaneously for improved surface display. When the two proteins are
induced simultaneously, flow cytometry reveals that BPTI surface display levels are
stimulated about 20% while D1.3 surface display levels decrease about 25% (Figure
2.3.3).
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Figure 2.3.3-Coexpression of Surface-Displayed BPTI and D1.3. Surface-displayed
BPTI and D1.3 show different responses to their co-expression inside the same cell (dark
bars) contrasted with cells expressing one protein only (light bars). BPTI display
improves in co-expressing cells, but D1.3 display is negatively impacted. Expression
levels are normalized to the single protein expressing mean surface display fluorescence,
and the error bars indicate one standard deviation.
The decrease in D1.3 surface display is not due to a shortage of agglutinin-l fusion
partner as additional galactose-induced expression of the Agal gene yields no increased
signal (Figure 2.2.4).
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Figure 2.3.4-Over-expression of CEN Agal. An additional CEN copy of galactose
induced Agal has no effect on the surface expression levels of D1.3 in comparison to an
empty pRS314 control vector in co-expressing cells.
From this result, it appears that the cell is underutilizing its BPTI secretory capacity in the
single-expressing strain, and it seems that co-expressing D1.3 stimulates the cell to take
advantage of more of its inherent capacity for BPTI. The negative effect BPTI has on
D1.3 expression could be due to enhanced secretory stress imposed by co-expression or
the monopolization of folding chaperones that are needed to successfully fold D1.3. To
determine whether folding chaperones are limiting under co-expressed conditions,
additional CEN copies of the ER chaperones BiP (Kar2) and protein disulfide isomerase
(PDI) were expressed in BPTI/D.13 surface displaying cells. High levels of galactose
and GPD promoted BiP as well as galactose promoter PDI have a beneficial effect on
D1.3 suggesting that protein folding chaperones are limiting under co-expressing
conditions (Figure 2.3.5, A). High-level expression of these chaperones seems has little
effect on BPTI display.
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Figure 2.3.5-Chaperone Expression in Co-expressing Cells. High levels of PDI and
BiP expression in co-expressing cells have a beneficial effect on D1.3 expression (A) but
little effect on BPTI expression (B) compared to wild-type (pRS316). BiP is expressed
under galactose or GPD-induced promoters.
These results are quite similar to the results obtained from co-expressing these
same chaperones with secreted forms of BPTI [32] and scFv [7] further suggesting a
linkage between yeast surface display and secretion. The display improvement that
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chaperone co-expression imparts on D1.3 supports the hypothesis that a BPTI-induced
shortage of folding helpers is responsible for the shortfall in D1.3 surface expression.
Furthermore, as these chaperones are not necessarily needed in high levels to fold BPTI,
any co-expression imparted decrease in their levels will not have much impact on BPTI
folding. The improvement in expression could also be due to improvement in the
Agalp/Aga2p interaction and not to processing improvements of the fused cargo.
In order to understand the fate of the D1.3 that is not surface displayed,
fluorescence imaging of intracellular D 1.3 was performed on D 1.3 only expressing and
co-expressing cells. Intracellular analysis showed that non-secreted D1.3 was confined to
the vacuole where it formed punctate bodies. The protein is probably degraded in wild-
type yeast cells but remains intact inside the vacuole due to the pep4/prb deletions that
decrease proteolysis in the organelle. Although the number of integrations in the two
strains is the same (Figure 2.3.6), the co-expressing cells exhibited increased levels of
vacuolar aggregation on a cellular as well as a population-wide scale (Figure 2.3.7).
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Figure 2.3.6-Verification of D1.3 Copy Number. Integrated D 1.3 and the control gene
GPD1 were PCR'ed from varying dilutions of chromosomal DNA. After obtaining a
range where product concentration was a strong, linear function of template concentration
for both D1.3 only and co-expressing cells, it was determined that the ratio of GPD1 to
D1.3 PCR product was the same for both strains across the range of relevant dilutions
(0.05 to 0.1 for D1.3 only and 0.01 to 0.05 for the co-expressing strain).
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Figure 2.3.7-Intracellular Retention of D1.3. Cells expressing surface-displayed D1.3
alone (A) retain less intracellular D 1.3 (green dye) inside the vacuolar compartment
(vacuole membrane shown in red) compared to cells coexpressing D1.3 and BPTI (B).
Co-expressing cells also show swelling. The yeast nuclei are stained with DAPI and
appear blue.
Surprisingly, these results suggest that BPTI co-expression affects D1.3 traffic in such a
way as to increase D1.3 levels in the late secretory pathway. Co-expression also results
in increased levels of cellular swelling as indicated by microscopy as well as light
scattering (data not shown). To determine if any D 1.3 successfully traverses the
secretory pathway but avoids surface display, supernatant levels of D1.3 were also tested
in co-expressing and single-expressing cells (Figure 2.3.8).
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Figure 2.3.8-Secreted D1.3 in Co-expressing Cells. Co-expressing cells secrete more
D1.3/Aga2 fusions into the supernatant than cells expressing D 1.3 only. This difference
is exacerbated when secreted D1.3 is normalized to the cell density of the culture.
Analysis of the yeast supernatant shows that despite the decreased levels of surface
fluorescence and elevated levels of vacuolar retention, there are similar levels of D1.3
found in the supernatant of co-expressing cells as determined by Western blot. However,
the real impact is made when factoring in the slow growth rate that occurs with co-
expression. When extracellular D 1.3 levels are normalized to culture cell density, the co-
expressing cells yield a ten-fold increase in D1.3 secretion. Furthermore, labeling cell
I
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surface bound lysozyme with the supernatant indicates that at least some of this protein is
well folded (Figure 2.3.9).
Figure 2.3.9-Functionality of Secreted D1.3-Aga2 Fusions. Supernatant from D1.3
surface displaying, co-displaying, and a 4m5.3 secreting negative control were mixed
with lysozyme-labeled cells. D1.3 binding was detected using the c-myc epitope tag
indicating that at least some of the secreted D 1.3-Aga2 is functional.
With the inclusion of intracellular and extracellular as well as surface expressed D1.3 into
the material balance, it appears that BPTI co-expression stimulates D 1.3 flux through the
late secretory pathway. A quick check can confirm this increase. A 25% drop in surface
display assuming -5x10 4 fusions per cell on the surface (data not shown) would mean
about 1.25x10 4 proteins or, given the culture density of 3 OD600 , about 0.02 mg/L of
surface displayed protein left unaccounted for. This tiny number is much less than the
co-expression stimulated increase found in the supernatant without even considering the
increase in the vacuolar protein.
2.3.3 Co-expression and the Unfolded Protein Response
The previous experiments have demonstrated that co-expression of a well folded,
relatively thermostable protein stimulates the secretion of a less well-behaved companion
protein. Microscopy and supernatant levels of D1.3 show a large increase in protein flux
through the late secretory pathway. This large flux could be the result of aberrant
processing and degradation in the endoplasmic reticulum. Because both folding and ER-
associated degradation (ERAD) are intimately linked to secretory stress, we can
determine the differences in stress levels by measuring the unfolded protein response
(UPR) with a green fluorescent protein (GFP) reporter gene. The UPR of BPTI and D 1.3
single expressing cells as well as co-expressing cells is shown in Figure 2.3.10.
Figure 2.3.10-UPR in Single Expressing and Co-expressing Cells. Cells co-
expressing BPTI and D1.3 show significantly more secretory stress than cells expressing
BPTI alone as measured by a UPR/GFP reporter gene. Most of the secretory stress
comes from the expression of D1.3. GFP signal in cells not expressing either protein is
shown as a negative control.
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It can be seen from the UPR reporter gene that D 1.3 imparts significantly more
secretory stress on the cell than BPTI with marginally more stress being imparted by co-
expression. Although little difference between D1.3 and co-expression induced stress is
seen, it could be hypothesized that the five fold increase in secretory stress imparted by
co-expression could stimulate the increased production of BPTI through one of the many
modifications via the unfolded protein response. To test this theory, the UPR was
artificially manipulated using an active, spliced Hacl gene that was expressed through a
doxycycline titratable promoter. This gene was transformed into co-expressing yeast and
the range of accessible UPR induction levels was measured with the GFP reporter gene
(Figure 2.3.11).
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Figure 2.3.11-Hacl Construct and Titration. A titratable, constitutively active version
of Hac I was constructed by ligating the spliced version of the Hac gene behind the
doxycycline regulated CYC 1 promoter (A). The construct imparts decreasing levels of
Hac 1 gene transcription as doxycycline in the media is increased as measured by the
UPR/GFP reporter plasmid (B). Concentrations of doxycycline in the induction media
are indicated. A wild-type control (pRS316, no UPR induction) is shown.
The GFP test showed a ten-fold range of UPR induction attained by adding varying
amounts of doxycycline. The highest concentration of doxycycline yielded a UPR
response similar to the Hacl minus pRS316 control. Once the Hac 1 construct had been
functionally verified, it was tested in co-expressing cells induced in media with varying
concentrations of doxycycline (Figure 2.3.12).
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Figure 2.3.12-Hacl' Titration. Constitutive activation of the UPR has a graded negative
impact on D1.3 (A) and BPTI (B) expression in co-expressing cells. Concentrations of
doxycycline in the induction media are indicated. A wild-type control (pRS316, no UPR
induction) is shown.
Tests with the constitutive induction of the UPR via the active form of Hac 1 show
that any artificial induction of the UPR has a negative effect on surface expression. This
result would suggest that the elevated levels of the UPR imparted by D 1.3 co-expression
are not responsible for the increase in BPTI surface expression. Furthermore, the
marginal increase in the UPR brought about by co-expression would also suggest that the
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source of the increased flux through the late secretory pathway is not due to UPR-
mediated changes in the ER.
2.3.4 Secretory Co-expression
The results presented above would suggest that the increase in protein flux
through the late secretory pathway is not caused by secretory stress in the endoplasmic
reticulum. It may be that BPTI and D1.3 encounter a saturatable trafficking step such as
a protein sorting step in the later part of the secretory pathway that usually results in
retrograde motion or outright degradation. Earlier studies have shown that misfolded
protein can be rescued from as far as the trans-Golgi by interactions with BiP. This late
secretory pathway retrieval could explain the co-expression phenomenon. Because BPTI
is better expressed than D1.3, it stoichiometrically outnumbers D1.3 in the Golgi thus
engaging more of the sorting receptors and preventing D 1.3 from being trafficked to a
degradative or retentive pathway (Figure 2.3.13). A change localized to the late Golgi
could also explain why there is such small improvement in the secretory stress in the ER
despite the massive increase in flux going through the pathway.
retrograde transport/
degradation
o BPTI
*yA D1.3
o sorting
protein
sorting
compartment
Toendosome/
---- I I C |UIo
o g
To surface
Figure 2.3.13-Mechanism for BPTI-Induced D.13 Secretory Improvement. BPTI
and D 1.3 are trafficked from the ER or post-ER compartment to a sorting compartment.
There, the secreted proteins engage retention proteins that impede their progress to
compartments downstream and may traffic them to previous compartments or to
degradation. Because BPTI constitutes a significant stoichiometric majority of the
protein, it outcompetes D. 13 for binding to the retention protein leaving more D 1.3 to be
trafficked to the surface and the vacuole. The competition also yields a slight increase in
BPTI surface-directed traffic.
This enrichment through competition would result in a great increase in the flux
of the less well-expressed protein while also mildly improving the vacuole or surface
directed traffic of the more well-expressed protein which is exactly the situation
presented here. To determine if secreted forms of D1.3 could be stimulated using co-
expression, D1.3 was secreted in the non-surface displaying strain BJ5464a as well as the
isogenic surface displaying strain JAR200 with and without the BPTI-Aga2 fusion
I
(Figure 2.3.14A). The concomitant BPTI surface expression compared to singly
expressing surface displayed BPTI is shown in Figure 2.3.14B. It should be noted that no
BPTI-Aga2 was found in the supernatant for single or co-expression.
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Figure 2.3.14-Co-expression of Secreted D1.3 and Surface-Displayed BPTI. Co-
expression of surface-displayed BPTI and secreted D1.3 stimulates D1.3 secretion about
three-fold on a per cell basis. Little effect is seen with Agal overexpression alone-
JAR200 (A). Co-expressing cells also exhibit slightly more surface displayed BPTI than
single BPTI expressing cells (B).
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To test the generality of the co-expression approach, the single chain 4m5.3 was
also co-expressed in both BJ5464a and JAR200 behind two different prepro regions
imparting different levels of expression. The IL-2 (Q126R) mutant was also co-
expressed (Figure 2.3.15). While co-expression benefited all of the single-chains tested,
the IL-2 mutant did not secrete at all under co-expression conditions.
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Figure 2.3.15-Co-expression of Surface Displayed BPTI with Various Proteins. Co-
expression of surface displayed BPTI stimulates the secretion of D1.3, and 4m5.3 even
when expressed from different leader peptides. Concomitant expression of surface
displayed BPTI and the IL-2 (Q126R) mutant obliterated any IL-2 secretion.
2.3.5 Surface Display and Mutagenic Libraries
It should be noted at this point that a variety of libraries were used in conjunction
with yeast surface display in an attempt to isolate better secreting clones. Cells were co-
transformed with surface expressed BPTI and D1.3 as described above and screened with
C
cDNA, deletion, and randomly mutagenized libraries. The cDNA library turned up two
hits in the forms of Rps20p, a 40S ribosomal subunit, and cell wall protein 2 (CWP2), a
protein involved in cell wall stability and cellular resistance to low pH. Interestingly,
both of these cDNAs had integrated into the yeast chromosome although both were
initially expressed from a CEN-plasmid. CWP2 was the only cDNA that was
successfully isolated and subcloned into a new expression vector, but its expression in
cells tuned for high levels of BPTI expression ([32]) showed no improvement in BPTI
secretion. Similarly, no cDNA-imparted improvement was seen for BPTI surface
display.
The Stanford Yeast Deletion Library [33] was used to provide a loss of function
library for consideration. Iterative screening of the library showed that a two to three-
fold improvement in display was seen for both D1.3 and BPTI surface display levels
from the original library through the forth sort. The hits turned out to be deletions in
FCY22, a purine cytosine permease, and an uncharacterized open reading frame.
However, transformation of surface displayed BPTI or D 1.3 into fresh cells showed no
improvement over wild-type indicating an additional mutation or epigenetic factor
responsible for the improvement in expression.
Lastly, a library of random mutations created by treating co-expressing cells with
EMS was constructed and sorted. This library showed surface expression improvement
with each additional round of sorting and, in fact, most isolates of this sort did surface
display D 1.3 better than the wild-type. Interestingly, for some of these isolated clones,
the improvement in surface expression was dependent on growth in aerated cultures. One
of the clones isolated even showed a two-fold improvement in D 1.3 secretion; however,
attempts to identify the mutation were decided to be too tedious for the benefit gained
and other avenues for improved expression were sought.
2.4 Conclusions
Before mutations improving recombinant protein secretion in yeast can be
isolated, an effective proxy for secretory screening must be found. Yeast surface display
(YSD) has been thought to be an effective proxy because of its use of the secretory
pathway to shuttle proteins to the cell surface. Furthermore, previous studies have shown
a correlation between surface display and secretion for single-chain T-cell receptors
([31], and experiments described in the previous section have also demonstrated the
relationship between surface display and secretion for the two differently thermostable
proteins D1.3 and BPTI. To add even more evidence to support the correlation, the
effects of the folding chaperones BiP and PDI are similar when D1.3 and BPTI are
surface displayed to when they are secreted. Both chaperones tend to improve D1.3
expression while neither affects BPTI secretion. It was our intent to simultaneously
surface express these two proteins in the same cell, and use surface display to select
hyper-expressing mutants for both proteins using flow cytometry.
From the initial secretion and surface display experiments, it is clear that BPTI is
more effectively processed than D1.3. This difference may have something to do with
the thermostability of the proteins and their propensity to aggregate, form errant disulfide
bonds, misfold in general, or mis-traffic. Surprisingly, when these two proteins are co-
expressed, D1.3 surface expression levels decrease while BPTI surface expression levels
increase suggesting that co-expression has opposing effects on the folding or trafficking
of the two proteins. It should be no surprise that the cell is capable of processing more
BPTI as higher levels of BPTI expression have been obtained in yeast cells in the past
[28], but the inhibitory effect of D 1.3 is puzzling. Furthermore, it is difficult to imagine
an intracellular environment that favors the expression of one protein to the detriment of
the other.
To understand this problem further, we looked for D 1.3 in the supernatant and
directly inside the cell. Supernatant D 1.3 levels in co-expressing cells were elevated over
the single-expressing cells suggesting that not all D1.3-Aga2p fusions were successfully
captured on the surface. After taking cell density into account, this difference was even
greater (-10-fold). Similarly, intracellular fluorescence microscopy showed much more
D1.3 vacuolar retention in co-expressing cells than in single-expressing cells. Not only
was more D1.3 retained on an individual cell basis, but more cells throughout the
population exhibited vacuolar D 1.3 retention compared to the single-expressing cells. A
material balance shows that the increase in secreted protein is more than the concomitant
decrease in surface indicating that the surface displayed protein was not simply rerouted
to the supernatant. These results would indicate that contrary to what surface expression
might suggest, co-expressing cells actually have a higher flux of D1.3 traversing the late
secretory pathway than D 1.3 only expressing cells. Lysozyme binding indicated that at
least some of this excess secreted protein is functionally folded. These results suggest
that BPTI co-expression somehow stimulates the processing of D 1.3 and perhaps causes
it to miss covalent linkage to Agalp resulting in D1.3-Aga2p overflow into the
supernatant. Indeed, it has been shown that Aga2p can be an effective leader for
heterologous protein secretion [34, 35]. However, if this linkage failure is an intrinsic
part of the phenotype, it does not seem to be due to shortage of Agalp.
It is typically thought that most of the negative impact of heterologous protein
folding on the cell occurs in the endoplasmic reticulum. Consequently, we looked at the
effect simultaneous expression has on secretory stress in the ER by using a GFP reporter
gene of the unfolded protein response. These experiments indicated that D 1.3 imparts
significantly more stress on the cell than BPTI. It may be postulated in fact, that this
increase in secretory stress could be responsible for the increase in BPTI surface display.
Interestingly co-expression of both proteins imparts only a minimal increase in ER stress
compared to single D 1.3 expression despite the fact that there is five to ten times more
protein being trafficked through the late secretory pathway. It would seem that although
ER stress may have a beneficial effect on BPTI, the co-expression of the two proteins
does not perturb the ER environment as measured by secretory stress much more than if
D1.3 were expressed alone. A titratable version of the actively spliced UPR activating
transcription factor Haclwas created to determine if BPTI and D1.3 surface expression
varied with UPR levels. In fact, both BPTI and D1.3 surface levels were negatively
impacted by UPR suggesting that perhaps the increases in the late secretory levels of both
proteins is unrelated to the ER.
An alternative hypothesis for the BPTI-mediated late secretory increase in D 1.3
flux may be based around a late secretory pathway sorting step that plays a role in
whether heterologously expressed protein continues through the Golgi ultimately to the
vacuole or surface or whether it is retained and perhaps degraded or shuttled in a
retrograde direction to a previous organelle. The hypothesis is founded on the postulate
that there is a saturatable trafficking step in the medial secretory pathway (perhaps a
COPII vesicle or Golgi protein) that engages the secreted protein and causes it to be
retained or degraded thus having a negative effect on surface directed traffic. BiP could
be one candidate for this interaction. Recombinant proteins in the Golgi might interact
with BiP and be taken back into the ER instead of the surface. Because BPTI is better
expressed and ultimately better secreted in co-expressing cells, it can be presumed that
BPTI is present in higher concentrations inside this organelle and is more likely to engage
the sorting receptor. This competition between BPTI and D1.3 causes a substantial
increase in D1.3 protein flux in the late secretory pathway due to its failure to interact
with this inhibitory pathway. On the other hand, because BPTI is abundant to begin with,
one would expect the impact on its expression to be modestly beneficial. In fact, this is
exactly what happens. Co-expression results in drastically improved secretion of the
more unstable, misfolding prone protein D1.3 while having a mild effect on the better
expressed thus more competitive protein BPTI.
If the hypothesis outlined above is correct, then one would expect the
improvement in secretory directed traffic to be present whether the protein is expressed
as an Aga2p fusion or not. Indeed, secreted D 1.3 co-expressed with surface displayed
BPTI does show a three-fold improvement in secretion compared to single-expression
alone. The difference in the effect of BPTI on D1.3-Aga2p fusion versus D1.3 secreted
constructs is probably due to the beneficial effects of the Aga2p fusion that can be an
effective leader sequence as described above. When secreted 4m5.3 is co-expressed with
surface displayed BPTI, a smaller beneficial effect is seen. Perhaps 4m5.3 being a better-
expressed protein is a better competitor for the sorting protein than D 1.3, so the effect is
not as exaggerated. Interestingly the IL-2 Q 126R mutant failed to secrete at all in co-
expressing cells perhaps suggesting a differently localized bottleneck for IL-2 secretory
expression.
Of course the scheme outlined above is just a hypothesis until the sorting receptor
in question is identified and verified. To positively identify the receptor in question, one
could screen a library of loss of function mutants for improved D 1.3 secretion. However,
due to the discrepancy between D 1.3 surface display and surface directed flux as well as
the failure of surface display to identify any useful mutants in the screens described
previously, it appears that yeast surface display is not a sufficient screening proxy for
such a task.
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Chapter 3: Cell Surface Secretion Assay
3.1 Introduction
Considering the results of the surface display screens as well as the data obtained
from the scFv and BPTI co-expression studies, it is clear that a more faithful screening
proxy for secretion is needed as Aga2 fusions do not accurately represent protein flux to
the surface. The discrepancy is probably due to inefficient Agal/Aga2 disulfide bond
formation, inefficient Agal/GPI anchoring, or abnormal trafficking and folding patterns
due to the addition of the Aga2 fusion. An ideal screening system would utilize soluble
protein expression thus negating the need for extra folding steps necessary for fusion
expression. Additionally, the ideal assay would use a minimally intrusive method to link
secretory phenotype to genotype in a manner that could be analyzed in a high-throughput
assay such as flow cytometry.
The most promising family of secretory cytometry screens is the affinity matrix
assays. These screens involve the application of a matrix to the cell wall or membrane
that captures protein as it is secreted. Frequently this matrix is made of a protein such as
an antibody that has an affinity for the secreted protein. This method has been used to
screen antibody secretion from hybridoma cells as well as cytokine secretion from T
lymphocytes [1]. Additionally, this assay was used to select CHO cells with enhanced
antibody secretion under selective [2] and nonselective [3] conditions and was also used
to capture a breast tumor antigen antibody secreted from a myeloma cell line [4].
Although affinity matrix technology has been used in mammalian cells, it has
never before been reported for yeast. It is our goal to develop an affinity matrix type
assay as a proxy for heterologous protein secretion in S. cerevisiae. Although we develop
this method using the scFv/antigen combination of 4m5.3 and fluorescein, we also show
that this Cell Surface Secretion Assay (CeSSA) can be used for a variety of proteins.
Furthermore, we determine the single-pass enrichment of a hyper-secreting clone out of a
background population of wild-type secretors. To enhance usefulness of this assay even
further, we develop a temporal CeSSA model to assist in sort design and execution which
could be applicable to any cell type. This model is then used to predict sort enrichment
levels of hyperproductive clones given a particular sort gate. These experiments illustrate
a proven, robust method for screening better secreting clones out of a library of yeast
mutants.
3.2 Experimental Protocol
3.2.1 Strains, Plasmids, and Growth
To create the yeast strains used for the 4m5.3 secretion specificity experiments,
the yeast strain BJ6454a (mata ura3-52 trpl leu2Al his3A200 pep4::HIS3 prblAl1.6R
can1 GAL) was transformed with the uracil-marked CEN-plasmid pRS4m5.3 as well as
pRS314 using the Frozen-EZ Yeast Transformation Kit II (Zymo Research, Orange, CA).
Yeast in the general CeSSA were transformed with pRSD1.3 or pJABwtBPTI-S1 (FLAG
and c-myc tagged BPTI). The integrating plasmid p14m5.3 was constructed by
subcloning 4m5.3 from pRS4m5.3 into pRS306 with the restriction enzymes KpnI and
SacI (New England Biolabs, Ipswich, MA). BJ4m5.3 was then created by
electroporating 7.1 ýtg of NcoI cut p14m5.3 into BJ5464a. The high secreting strain used
in the CeSSA enrichment assay was created by transforming tryptophan-marked
pRS4m5.3 into BJ4m5.3. For secretion, yeast were grown overnight at 300 C in 5 mL
SD-CAA + 30 jil 20 mg/L tryptophan when needed to an OD600 -8. Cells were then
spun down and resuspended in 5mL YPG/BSA and incubated 24 hours. A detailed
transformation protocol is given in Appendix 1.1.
3.2.2 4m5.3 Fluorescein Quench Secretion Assay
The fluorescein quench assay was used to determine supernatant 4m5.3
concentrations [5]. 10 gtM fluorescein (Sigma) was added to 500 gL of supernatant
diluted in 2.5 mL assay buffer (3 mL total) in 3 pL increments. A detailed protocol is
given in Appendix 1.5.
3.2.3 FITC, NHS-PEG-fluorescein, and NHS-PEG-biotin/avidin labeling
Cells were inoculated then induced for secretion for twelve hours. 1 OD 600 Of
cells was washed three times with 1 mL carbonate buffer. Cells were resuspended in 30
gl 9 mg/mL fluorescein isothiocyanate, FITC (Sigma) or 10 ld of 0.2 mg/jl 3.4 kDa
NHS-PEG-fluorescein (Nektar Therapeutics, Huntsville, AL) dissolved in carbonate
buffer where they were incubated at room temperature in the dark for thirty minutes with
vortexing every ten minutes before being washed three times with 1 ml PBS/0.1% BSA.
For the CeSSA generality experiments, cells were labeled in 10 pd of 0.2 mg/pl
3.4 kDa NHS-PEG-biotin (Nektar Therapeutics) for thirty minutes at room temperature
following the initial carbonate buffer wash. Cells were then washed three times in 1 mL
PBS/BSA and labeled with 20 ptl 10 mg/mL avidin (Zymed Laboratories, San Francisco,
CA) dissolved in PBS for 20 minutes at room temperature. After three more PBS/BSA
washes, the cells were resuspended in 30 pl 10 gM biotin-lysozyme (Sigma-Aldrich)
dissolved in PBS or 30 ptl of 1.1 mg/mL Bio-M2 anti-FLAG antibody (Sigma-Aldrich)
and incubated for 20 minutes at room temperature before being washed another three
times in 1 mL PBS/BSA.
3.2.4 Yeast CeSSA Assay
Cells were labeled with NHS-PEG-fluorescein or the NHS-PEG-
biotin/avidin/biotinylated-protein constructs and inoculated into YPG/PEG on plates.
The plates were incubated at 300C for approximately 9 hours for the enrichment
verification and specificity assays and for variable amounts of time for the time course
assay. Fluorescein labeled cells were eluted in 15 mL 0.1 ptM FITC/dextran (2 MDa,
Sigma) dissolved in PBS/BSA, and biotin labeled cells were eluted in 15 mL PBS/BSA.
The cells were spun down at 2200 rpm for five minutes and washed in 1 mL PBS/BSA.
Cells secreting D 1.3 or BPTI were incubated on the plate for 12 hours. A detailed
protocol is given in Appendix 1.4.
3.2.5 Flow Cytometry
For the fluorescein accessibility assays, 1 OD 600 of FITC or NHS-PEG-
fluorescein labeled cells were incubated in 0.5 mL yeast supernatant containing FLAG-
tagged 4m5.3 (-10 mg/L) for one hour at 300 C before washing in 500 pl PBS/BSA. The
pellet was resuspended in 50 pl 40 p.g/mL M2 antibody (Sigma) diluted in PBS/BSA and
incubated in the dark on ice for 20 minutes. After a 500 pll PBS/BSA wash, the cells
were resuspended in 50 .l 20 gg/mL Alexa-Fluor 610-R-phycoerythrin goat anti mouse
IgG (Invitrogen, Chicago, IL) diluted in PBS/BSA and incubated 20 minutes on ice.
After labeling, the cells were analyzed on a Coulter Epics XL flow cytometer (Coulter,
Miami Lakes, FL). All CeSSA assays utilizing 4m5.3 secreting cells were labeled in a
similar manner excepting the initial incubation in 4m5.3 containing supernatant.
In the generality assays, the cells were labeled with 50 p1l 20 ptg/mL chicken
anti c-myc antibody (Invitrogen) diluted into PBS/BSA and were incubated on ice for 20
minutes in the dark. After washing the cells were resuspended in 50 p.l of 40gpg/mL
Alexa488-conjugated goat anti-chicken antibody (Invitrogen) in addition to 10p.g/mL
streptavidin-R-phycoerythrin (SAPE), and incubated for 20 minutes on ice in the dark.
BPTI was labeled with 20 ptl of 24 p.M Alexa488-conjugated trypsin as well as SAPE.
3.2.6 Cell Sorting
Doubly transformed high secretors were doped into a population of singly
transformed low secretors at ratios of 1:50, 1:100, or 1:500 in a total of lx107 cells and
treated in the yeast CeSSA for nine hours before being run on a Cytomation MoFlo Cell
Sorter. Approximately 10,000 cells were sorted from the fluorescein positive
subpopulation, and approximately 3,000 were sorted from the enrichment gate. 1:1 and
1:10 dilutions of the sort were plated onto YPD or SD-CAA plates, and the resulting
colonies were counted after two days of incubation at 300 C.
3.2.7 Time Course Modeling
A diffusion/reaction model of the CeSSA was performed using parameters
derived from experiment or found in the literature. The diffusivity of 4m5.3 in YPG/PEG
was estimated from the aqueous diffusivity of EGFP, a protein with a similar molecular
weight (27 kDa) to 4m5.3 (30 kDa) [6] and modified via the Stokes-Einstein Diffusion
kbTEquation: Df e = to account for the fourteen-fold PEG-induced increase in6;ur
viscosity [7]. Dfree is the protein diffusivity, kb is Boltzmann's constant, T is the absolute
temperature, gp is the viscosity of the solution, and r is the hydrodynamic radius of the
protein-a parameter that is proportional to the cube root of the molecular weight.
The intrinsic secretion rate, r, was found by growing and inducing a culture of
integrated 4m5.3. After eight and twenty hours, samples of supernatant were taken and
the concentration of 4m5.3 was measured. The accumulation of 4m5.3 was normalized
to time and cell concentration in the induction media. The CeSSA cell growth rate for
the model was determined by taking the logl/2 of the fluorescein positive fraction of the
population at each time point and then using that number (the number of cell doublings)
to estimate cell number. The resulting cell number was then fit to a quadratic equation in
time: cell number = 0.034t2-0.55t+3.49, with an R2 of 1.0 using Microsoft Excel
(Microsoft, Redmond, WA).
The initial number of fluoresceins on the cell surface was determined by
comparing the mean fluorescence of labeled cells to Bang's Beads Quantum FITC MESF
High Level fluorescein calibration standards (Bang's Laboratories, Fishers, IN).
Modeling was performed using Matlab Software (MathWorks, Natick, MA).
3.3 Results
3.3.1 CeSSA Development
The ultimate goal of a flow cytometric secretory screen is to link a screenable
secretory phenotype to a particular clone. To accomplish this, a ligand was tethered to a
secreting cell allowing the secreted protein to be captured on the cell surface where it
could be labeled and analyzed via flow cytometry (Figure 3.3.1).
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Figure 3.3.1-Cell Surface Secretion Assay (CeSSA). The yeast cell is labeled with
ligand that binds the secreted protein. As the epitope-tagged protein is secreted, it is
captured on the cell surface where it can be labeled with a fluorescently tagged antibody
against the epitope tag. This labeling provides a cytometric screening proxy for
secretion.
The scFv 4m5.3 and its ligand fluorescein were chosen as a model system because
fluorescein labeled cells are fluorescent themselves and provide a readily accessible
measure of labeling efficiency. Furthermore, the interaction between fluorescein and
4m5.3 is extremely tight with a half life on the order of a couple of days [5, 8] making the
binding between the two essentially irreversible on time scales relevant to the screen.
The first attempt at labeling cells with fluorescein utilized fluorescein isothiocyanate
(FITC), which is a primary amine reactive form of fluorescein capable of forming
covalent bonds to cell surface proteins. Although FITC sufficiently labeled the cells, it
proved inaccessible to exogenously added 4m5.3 (Figure 3.3.2). This inaccessibility is
probably due to steric crowding due to the yeast cell wall or 4m5.3 tertiary protein
structure. To overcome the crowding problem, fluorescein was attached to the cell wall
via a polyethylene glycol (PEG) linker with the primary amine reactive moiety N-
hydroxysuccinimide ester (NHS) on the other end. This linker was essential for the
ability of surface labeled fluorescein to bind to 4m5.3.
Figure 3.3.2-Linker-mediated Fluorescein Accessibility. A 3.4kDa polyethylene
glycol linker attached to fluorescein is essential for 4m5.3 binding to cell surface
immobilized fluorescein as indicated by flow cytometry measuring exogenously added
4m5.3.
Once ligand accessibility is ensured, we established a procedure for growing and
inducing protein expression in cells consistent with standard cell culture yet conducive to
cytometric screening. Performing the assay in standard five-milliliter liquid cultures
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resulted in non-specific labeling due to convective mixing. To eliminate the mixing, cells
were induced in standard 5 mL culture tubes with YPG/BSA for twelve hours then
labeled and transferred to a solution of YPG/BSA/30wt% PEG (8 kDa). This high
viscosity induction media hinders diffusion of secreted 4m5.3 thus attenuating non-
specific labeling. The cells and media were applied to a plate in a thin layer (two
millimeters) to ensure adequate aeration and then incubated at 300C in a static culture.
The cells could then be washed from the plate, labeled for flow cytometry, and sorted
(Figure 3.3.3). This process is repeated until suitable clones are isolated as determined
by a traditional secretory assay.
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Figure 3.3.3-4m5.3 Cell Surface Secretion Assay (CeSSA). A population of 4m5.3
secreting cells is grown and induced in 5mL culture tubes and then labeled with NHS-
PEG-fluorescein. The cells are then incubated in a static culture of YPG/PEG where
secreted protein is captured. After sufficient incubation, the cells are eluted in
PBS/fluorescein, labeled with fluorescent antibodies and screened with FACS. Isolates
from the sort are expanded and run through the assay again.
To ensure that a secreting cell only captures protein that it secreted itself, a test of
capture specificity was undertaken. Cells transformed with a CEN-plasmid containing
FLAG-tagged 4m5.3 were analyzed with the CeSSA. After the assay, secreting cells
were positive for both fluorescein and 4m5.3 (Figure 3.3.4A, gate a) when analyzed by
flow cytometry. Cells that had lost their CEN-plasmid were positive for fluorescein but
negative for 4m5.3 (Figure 3.3.4A, gate b). Because new cell growth is limited to the
bud, surface fluorescein does not pass on to daughter cells. Consequently, non-secreting
mother cells can be differentiated from daughter cells (Figure 3.3.4A, gate c) by
fluorescein fluorescence. A histogram of 4m5.3 expression derived from the fluorescein
positive subpopulation (gates a and b) is shown in Figure 4.4.4B.
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Figure 3.3.4-4m5.3 Surface Capture Specificity. Only cells secreting 4m5.3 capture it
on their surface (A) as evidenced by a secreting 4m5.3 positive peak (gate a) and a non-
secreting negative peak (gate b) in the PEG-fluorescein positive subpopulation. A PEG-
fluorescein negative population made of non-labeled daughter cells (gate c) also
accumulates as cells divide. Data drawn from gates a and b were fit to the sum of two
log-normal distributions (B).
3.3.2 CeSSA Generality
To extrapolate this assay to other types of protein, biotin was used as a capture
ligand in place of 4m5.3. This method is most similar to the matrix affinity techniques
applied in Manz et. al. (1995) and Borth et. al. (2000). Cells were labeled with NHS-
PEG-biotin, followed by avidin, and then a biotinylated protein that served as the capture
protein. This biotinylated protein could be a ligand for the secreted protein or an
antibody against an epitope tag on the secreted protein. In one example, a c-myc tagged
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version of the scFv D1.3 was captured using biotinylated lysozyme. Captured D1.3 was
detected using an anti-c-myc antibody, and mother and daughter cells were discriminated
by labeling cells with streptavidin-phycoerythrin (SAPE) that binds to free biotin on the
cell surface (Figure 3.3.5A). Flow cytometric analysis again shows an actively secreting
positive peak and a non-secreting negative peak in the SAPE positive subpopulation
(Figure 3.3.5B).
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Figure 3.3.5-D1.3/biotin-lysozyme CeSSA. Cells are labeled with NHS-PEG-biotin,
avidin, and then biotinylated-lysozyme. Secreted c-myc-tagged D1.3 is then captured by
the lysozyme where it can be labeled with an anti-c-myc antibody and analyzed by flow
cytometry (A). A mixed population of cells analyzed by the CeSSA show a non-
secreting negative peak and an actively secreting positive peak (B).
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As another demonstration of CeSSA generality, FLAG-tagged BPTI-bearing CEN
plasmids were transformed into cells and captured by immobilizing a biotinylated version
of the anti-FLAG antibody M2 on the surface with an avidin sandwich as described
above (Figure 3.3.6A). Labeling with Alexa488-tagged trypsin and SAPE revealed a
secreting BPTI positive subpopulation and a non-secreting BPTI negative population in
the SAPE positive subpopulation (Figure 3.3.6B).
avidin hintn-A NHS-PI
B
sin/Alexa488
Figure 3.3.6-BPTI/biotinylated anti-FLAG CeSSA. Cells are labeled with NHS-PEG-
biotin, avidin, and then biotinylated-M2 (anti-flag) antibody. Secreted flag-tagged BPTI
is captured on the cell's surface where it can be labeled with Alexa488-tagged trypsin (A)
and analyzed by flow cytometry. A mixed population of BPTI secreting cells
demonstrates an actively secreting positive subpopulation and a non-secreting negative
subpopulation (B).
These two experiments demonstrate that the CeSSA can be used to capture most any
secreted protein via an immobilized ligand or antibody.
3.3.3 CeSSA Screening Verification
Although the assay has been proven to capture protein specifically, if it is to be
used for sorting, it is also important to show that rare, high secreting clones can be
selected from a background of wild-type secreting cells. To create high secreting clones,
BJ4m5.3 was transformed with an additional copy of 4m5.3 in the form of a tryptophan-
bearing CEN plasmid. These transformants can be distinguished from wild-type
BJ4m5.3 by their ability to grow in SD-CAA. After growth and induction, supernatant
4m5.3 concentrations in the doubly transformed strain were three times higher per cell
than in wild-type BJ4m5.3 (Figure 3.3.7).
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Figure 3.3.7-4m5.3 Secretion from Integrations and Centromeric Plasmids. Flag-
tagged 4m5.3 was secreted in a strain carrying a genomically integrated copy of the gene
or from a strain carrying the integration in addition to a differently marked CEN-plasmid.
The strain with two nutritionally marked copies secreted 4m5.3 about three times better
per cell than the integration alone.
To determine the enrichment that the CeSSA can provide, the higher secreting
clones were doped into the wild-type clones in ratios of 1:50, 1:100, and 1:500. These
mixtures were labeled with PEG-fluorescein, run through the CeSSA, and sorted by
FACS. The top 0.3% of the fluorescein positive subpopulation was selected for
improved secretion (Figure 3.3.8A, gate a) and in another sample, all of the fluorescein
positive cells were taken for comparison (Figure 3.3.8A, gates a and b). The isolated
clones from both sorts were immediately plated on non-selective YPD or double
transformant selective SD-CAA. A comparison of colony count between the two
samples plated on SD-CAA gives an indication of enrichment while the colony count on
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YPD serves as a plating control. These comparisons of colony count indicate a single-
pass enrichment between 23 and 45-fold for the 1:50 and 1:500 dilutions respectively.
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Figure 3.3.8-CeSSA Verification. Higher secreting cells were spiked into a population
of wild-type secretors in ratios between 1:50 (shown) and 1:500 and were passed through
the yeast CeSSA. After cytometric labeling (A), the top 0.3% (gate a) as well as all the
fluorescein positive cells (gate b) were sorted and plated on selective and non-selective
media. Based on the resulting colony count, the CeSSA was found to yield between 23
and 45-fold enrichment of the higher secreting clone (B). The average enrichment is also
shown with one standard deviation indicated by the error bars.
These levels of enrichment are suitable for cytometric screening and indicate that a rare
hyper-secreting clone could be pulled down from a yeast library of significant size (106)
in about four passes. Moreover, these enrichment levels are obtained against a
background of secreting cells rather than a background of non-secreting cells indicating a
fairly fine signal resolution.
3.3.4 CeSSA Modeling
In order to best tune the screening parameters and predict sorting enrichments, a
mathematical model of the yeast CeSSA was developed. This model illustrates the time-
dependent evolution of cell surface protein capture for a cell with a given secretory
output. A few assumptions are necessary for the implementation of the model. First, the
resistance to protein diffusion between the immediate extracellular environment and a
tethered receptor is negligible compared to the resistance to diffusion between cells. This
assumption is most valid for dilute protein solutions and for cells with a large amount of
tethered ligands. Secondly, binding between ligand and protein is assumed to be
irreversible. This assumption is particularly true for the 4m5.3/fluorescein interaction
due to the slow off rate. Finally, the overall reaction rate is assumed to be diffusion
limited so that the rate can be described as the rate of protein diffusion from the
extracellular environment to the cell surface.
Once released from a cell, protein (for this illustration, secreted 4m5.3) can either
escape from the cell into the bulk phase with some probability y or be captured by the cell
with probability 1-y (Figure 3.3.9). In addition, protein that has escaped cell capture can
diffuse to a new cell and bind tethered ligands (in this case, PEG-fluorescein) on its
surface.
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Figure 3.3.9-CeSSA Model Schematic. Once secreted from its parent cell (white) at a
rate of P, a protein (in this case, 4m5.3) may either diffuse into the bulk with probability y
or bind to free surface attached fluorescein F to create a 4m5.3/fluorescein complex, MF.
Bulk 4m5.4, B, can either bind a secreting cell at rate Rbs or bind free fluorescein, U, on a
non-secreting cell (shaded) at a rate of &n.
A material balance around surface bound 4m5.3 can be written as
dMF 4 rA4D(1 -y)B (1)
= PP(1- y)+ (1)dt VB
where MF is surface bound protein (molecules), P is the intrinsic secretion rate
(molecules/h), A is the radius of the cell (cm), D is the diffusivity of 4m5.3 (cm 2/h), and
B/NB is the concentration of 4m5.3 in the bulk (molecules/cm 3). The first term on the
right hand side of the equation describes the rate at which secreted 4m5.3 immediately
binds to tethered fluorescein. This term is a measure of binding specificity. The second
term measures the rate at which tethered ligands bind protein from the bulk environment
Rbs
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and is an indication of non-specific labeling. Similarly, if a labeled cell is not secreting,
then the binding rate consists only of the bulk term:
dMU = 4rAD(1- yu)B (2)
dt VB
where MU is protein bound on non-secreting cells. Moreover, because total tethered
fluorescein (bound plus unbound) must remain constant over time, the material balances
around the tethered ligand on the cell is simply
dF dMF
-= (3)dt dt
dU dMUS= (4)dt dt
where F is free tethered ligand on secreting cells and U is free tethered ligand on non-
secreting cells. Bulk 4m5.3 concentration is a balance between secreted protein escaping
into the bulk and protein diffusing back to cell surfaces and binding tethered fluorescein
non-specifically:
dB 4MADBd= N{yP - [ ](2- y-)} (5)dt VB
where N is the initial number of cells on the plate. The first term in braces on the right
hand side of the equation describes 4m5.3 escaping into the bulk and the second term
describes 4m5.3 diffusing and binding secreting, y, and non-secreting, Yu, cells. When
solved simultaneously, these five equations describe how cells capture protein over the
course of the assay.
Model parameters were determined from literature and empirical data. The
escape probability, y, can be found by solving Fick' s second law of diffusion subject to
the boundary conditions that the rate of diffusion of the protein (4m5.3) to the tethered
ligand (fluorescein) is equal to the intrinsic reaction rate at steady-state [9, 10] and that
the protein concentration at long distances from the cell approaches the bulk protein
concentration (BNB). After solving this second order differential equation, one finds that
the overall reaction rate can be described as the inverse of the sum of the resistances due
to diffusion and intrinsic reaction:
1 1
ko=vera (-I + )- ' (6)
kdean kdfk rxn
Additionally, because of the diffusion limiting reaction assumption described above, the
overall reaction rate constant can also be written as
koverao, = (1- y)kdi (7)
With some rearrangement it can be shown that
=  ff (8)
kdf +k
or
Y= (1+ )' (9)4 7AD
where k is the intrinsic reaction rate constant [ 11].
Because mother cells do not pass fluorescein to daughter cells yet daughter cells
also secrete protein into the immediate environment that can contribute to the signal, the
secretion rate P can be expressed as the product of the intrinsic secretion rate per cell and
the number of cells in a colony. The intrinsic secretion rate was found by inducing a
culture of 4m5.3 secreting cells and monitoring supernatant 4m5.3 accumulation over
time while normalizing for cell density. An expression for the number of cells in a
colony as a function of time was found by monitoring the accumulation of the fluorescein
negative population as the assay progressed and fitting the cell number determined from
that analysis to a quadratic equation. Although this equation has no physical meaning, it
does accurately describe cell division over the course of the assay.
The initial number of fluoresceins on the cell surface was determined to be
approximately 4.3x1 05 per cell and was acquired by comparing labeled cell fluorescence
to fluorescein flow cytometry calibration standards. Other parameters not described here
were found in the literature or from easily measurable assay attributes. These parameters
and their sources are summarized in Table 3.1. Using these values to
Table 3.I-CeSSA Model Parameter Values and Sources
Parameter Value Method of
Estimation
k, 2.3x10-11 Midelfort et. al.
Fluorescein/4m5. cm3 h-1 (2004)
3 binding on rate molecule-1
A, cell radius 2.5x10-4 cm
D, 4m5.3 2.2x10-4 cm2  Aqueous lysozyme
diffusivity h-1  diffusivity (Ario-
DuPont, 2000)
modified for PEG
solutions via Stokes-
Einstein equation
r, intrinsic 1.2x10 4  4m5.3 secretion in
secretion rate molecules YPG culture over 24
h-W hrs.
VB, bulk phase 9 cm3  Volume of assay
volume
N, number of cells 5x106 OD600 of cells added
to assay
Fo, U0, initial 3.2x105  Modified from
number of free fluoresceins 4.3x105 estimate
PEG-fluoresceins cell-1  obtained from
calibration beads
check the model assumptions outlined above, one finds that the reaction rate is indeed
diffusion limited the large majority of the time, and the number of tethered fluoresceins
on the cell surface is sufficient to assume a negligible diffusive resistance imparted by
diffusion to the tethered ligand compared to diffusion to the whole cell [12].
3.3.5 CeSSA Time Course
In order to validate the model, a CeSSA time course utilizing 4m5.3 surface
capture was performed for times up to twenty-four hours. 4m5.3-integrated cells were
mixed 1:1 with non-secreting cells, induced, and analyzed by CeSSA at incremental time
points up to the twenty-four hour mark. After labeling and cytometric screening, the
mean 4m5.3 signal was taken and normalized to the highest observed signal. These data
were plotted against the CeSSA model yielding normalized 4m5.3 signals between zero
and one. The model fit the data for secreting cells well after some minor modifications
such as decreasing the cell surface fluorescein concentration to 3.2x10 5/cell and
augmenting the intrinsic secretion rate to 1.2xl 04molecules/hr from an initial value of
lx10 4 molecules/h (Figure 3.3.10).
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Figure 3.3.10-Model of Yeast CeSSA Signal on Secreting Cells. The CeSSA model
was run for 4m5.3 binding on secreting cells. The error bars indicate one standard
deviation of three trials.
Similarly, the model also gave accurate predictions for non-secreting cells (Figure
3.3.11).
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Figure 3.3.11-Model of Yeast CeSSA on Non-secreting Cells. The CeSSA model was
run to predict 4m5.3 capture on non-secreting cells as an indicator of specificity. The
error bars indicate one standard deviation of three trials.
The deviation of the secreting population between model and experiment at 24 hours
could be attributed to poor cytometric labeling of the large number of cells that have
accumulated from one mother cell at that time point. Moreover, the inaccuracy at the 24-
hour time point of the non-secreting assay could be explained by the inaccessibility of
tethered fluorescein caused by steric crowding of daughter cells. Nevertheless, the model
is accurate up to 20 hours which includes most of the relevant screening time since the
secreting cells have reached saturation at that time point anyway. The model and
experiment show that 4m5.3 does not begin to accumulate on secreting cells until about
eight hours into the assay. This lag is probably due to inoculation shock caused by the
change in media or by the insensitivity of the cytometer at such low levels of
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fluorescence. This lapse was incorporated into the model by introducing an eight-hour
time lag. Another interesting feature of this analysis is the time lag between 4m5.3
accumulation on secreting cells and non-secreting cells. This span of eight hours
(between the eight and sixteen hour timepoints) seems to be the optimal time to screen
the cells as non-specific labeling is at a minimum. This lag also seems to suggest that
almost all secreted 4m5.3 is bound by surface fluorescein initially until enough ligand is
saturated to permit escape into the bulk. As expected, the model also shows that the
4m5.3 signal plateaus with the saturation of surface receptors. Furthermore, the time-
dependent progression of the 4m5.3 signal follows a sigmoidal curve first influenced by
signal amplification due to dividing cells and later influenced by the lack of available
fluorescein binding partners.
Now that the model has been sufficiently validated, it is used to predict the single-
pass enrichment rate in a hypothetical library sort where a three-fold better secretor is to
be picked out of a background of wild-type cells. For this, the model intrinsic secretion
rate was increased three-fold. The model showed that a three-fold better secretor would
demonstrate a three-fold increase in 4m5.3 signal mean compared to wild-type after nine
hours of the assay (Figure 3.3.12). This new mean was used to construct a new
hypothetical population distribution for the mutant. By comparing this new distribution
with the wild-type distribution as well as the actual 1:500 dilution sort data shown above,
one can determine the theoretical enrichment in a single sort given a specific sort
window. In this example a sort window of the top 0.3% is used to give a theoretical
enrichment rate of 60-fold (18% of improved secretor covered compared to 0.3% of wild-
type, Figure 4.12B). This number is similar to the 45-fold enrichment rate obtained
experimentally with sorting and plating inefficiencies being the chief contributors to the
discrepancies. This model is clearly useful in providing upper-limit predictions on sorts
and has proven to be accurate for typical library enrichments that will be described later.
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Figure 4.12-Theoretical Enrichment of Three-fold Higher Secreting Clone. The
CeSSA model was used to predict the temporal 4m5.3 signal on wild-type and 3x
secretors (A). The means of the lx and 3x secretors at nine hours were used to generate
hypothetical population distributions for the two clones (B). A 0.3% sort window is
drawn over the two populations to indicate the level of enrichment one could expect from
this sort. The distributions are overlaid onto actual lx data.
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3.4 Conclusions
Due to the intrinsic disconnect between phenotype and genotype in protein
secretion, there have been few high-throughput, comprehensive screens developed for
secretory improvement, especially in yeast. Most screens rely on tedious, low-throughput
techniques such as Western blots, halo assays, and suppression screens. The flow
cytometric method presented here provides an easy, high-throughput alternative to
traditional screening methods. Furthermore, this assay utilizes more industrial-like
fermentation conditions facilitating the transition from bench-top assay to industrial
production.
We present here a flow cytometric screening method that has been used to isolate
rare highly secreting clones from a background of wild-type secreting cells. Although the
screen described here has been developed for yeast, the method could be adapted for
screening with mammalian, insect, or other eukaryotic cell types. A previously described
assay utilizes mammalian cells to select for improved production of IgGs; however, yeast
morphology requires the use of a linker to separate the capture ligand form the
polysaccharide-laden and porous yeast cell wall. The yeast assay is necessarily a static
assay because the turbulent fluid flows in standard yeast culture causes an intolerable
amount of non-specific labeling. Although the static assay is different than standard
culture growth, it is a more accurate screening proxy than many plate-based assays
currently used in secretion screening. In addition, this screening method is superior to
traditional immunoblotting methods because it also selects for fully functional protein. In
fact mutant protein libraries could be screened for enhanced expression or activity using
this technique. This screen has been shown to be applicable to any protein with a
biotinylatable binder or any epitope-tagged protein with a biotinylatable antibody.
Finally, with enrichments on the order of thirty-five fold per pass, one could select an
enhanced secretory mutant out of a library as large as 108 in about five rounds of
selection, which would be impossible with Western blot or plate based screens. With the
ability to screen libraries of such size, little a priori information about the secretory
nature of the cell needs to be available unlike the detailed information that is sometimes
required for suppression screens.
Modeling the yeast CeSSA enables one to rationally design screening parameters
and sort gates as well as predict sort outcomes. The model demonstrates that most
secreted protein is captured at early time points and very few tethered ligands are labeled
non-specifically. From this result coupled with the time course assay described earlier,
one can find an optimal screening window between the initial inoculation shock and the
non-specific labeling that occurs at later time points. Initially, protein signal scales
linearly with secretion rate at these low time points, but as the capture ligand becomes
saturated, the lack of available ligand begins to dominate the kinetics and the signal
resolution begins to be lost. In addition to the secretion assay, this model also has
applications in the area of autocrine signaling. The system described here is quite similar
to autocrine signaling cascades present in many types of mammalian cells and cancers
[13-15]. Once model parameters such as autocrine secretion rate, surface receptor
population, and cell radius are determined, one could use this model to predict the
amount of time and cytokine necessary for an autocrine signaling cell to elicit a response
and to what extent cytokine signaling from one cell interferes with the function of
neighboring cells.
With the ability to predict single-pass enrichment rates from a given sort gate and level of
secretion, the speed at which a clone can be isolated from a large library can be
determined using the model. This analysis prevents lack of selection breadth due to
overselection or unproductive sorting due to underselection. Furthermore, gate sizes can
be analytically designed to prevent rare clone loss in early sorting rounds and overly
conservative gating in later rounds resulting in unproductive sorts. The assay described
here could be of great benefit to industrial and academic strain development as it is an
easily accessible method of selecting mutants with enhanced levels of protein secretion.
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Chapter 4: Directed Evolution of Alpha Mating Factor Leader
for Improved Secretion
4.1 Introduction
In Chapter 3 an effective method for screening mutant libraries for better
heterologous protein secretion was derived and modeled. It is know our intention to use
that assay to generate a more productive clone of S. cerevisiae for the secretion of the
scFv 4m5.3 and, if possible, other types of proteins. As discussed in Chapter 2, there are
many types of libraries to consider including deletions, overexpression, and mutagenic
libraries. However, the library to be discussed in detail here is centered on the
engineering of a better secretory leader peptide. Hopefully this improved peptide will be
able to boost the secretion of multiple proteins as well as pinpoint some key steps in
successful protein trafficking.
Newly translated secretion-directed polypeptides rely on their N-terminal amino
acid sequence or "pre" region to instruct the cellular machinery to direct them to the
secretory pathway. Pre regions, including the yeast alpha mating factor pre region
(MFalpp), typically consist of a positively charged N-terminus followed by a
hydrophobic middle region, and then a polar sequence just N-terminal to the signal
peptidase cleavage site [1]. Mutations to these sequences can have severe effects on
protein targeting to the ER [2]. In yeast nascent proteins can be translocated into the
endoplasmic reticulum (ER) either while they are being synthesized, co-translational
translocation, or after they have been translated, post-translational translocation.
Furthermore, it is thought that the translocation pathway is influenced by the sequence of
the pre region [3]. In contrast, with the exceptions of a few small polypeptides,
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mammalian cells co-translationally translocate almost all of their ER-directed protein [1].
However, MFalpp is typically translocated posttranslationaly [4]. Co-translationally
translocated proteins must be directed to the ER by a protein chaperone known as the
signal recognition particle (SRP). The SRP binds to the pre region of the translating
protein and is thought to slow translation enough to allow the migration of the
ribosome/SRP/polypeptide complex to the translocon pore in the ER [5]. Post-
translationally translocated proteins can enter the ER independent of SRP but do rely on
cytosolic chaperones, most notably Ssalp and Ydj lp, to maintain a more or less "linear"
form able to be translocated into the ER [1, 6, 7].
The pre region is translocated through the Sec61 complex as a hairpin loop such
that the N-terminus is maintained in the cytosol [1] and is then cleaved by the ER luminal
protein signal peptidase. In co-translational translocation, the driving force for
translocation is the ribosomal synthesis of the new polypeptide [8]. However, studies
with posttranslationally translocated proteins such as MFalpp indicate that nascent
proteins are translocated into the ER lumen in a BiP-mediated "Brownian ratchet"
mechanism. In this scheme, polypeptide diffusion is responsible for forward progress into
the ER lumen but BiP binding to translocated patches prevents retrograde motion
yielding a net forward motion [9].
In the ER the signal peptide sequence is cleaved by signal peptidase and N-linked
carbohydrates are added to the three glycosylation sites on alpha mating factor pro
(aMFlp). The three glycosylation sites are actually not essential to alpha factor
processing but their deletion greatly reduces alpha factor secretory competence and
increases intracellular retention of pro alpha mating factor in a form that is consistent
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with disruption of ER to Golgi transport [10]. N-glycosylation site deletions also
negatively effect the processing of insulin; however, N-linked glycosylation sites are not
needed to direct the secretion of heterologous proteins in general as synthetic pro regions
lacking glycosylation sites are capable of directing the insulin precursor protein into the
supernatant [11, 12]. Furthermore, studies indicate that the pro region is tolerant of in-
frame amino acid insertions, but not in-frame deletions [10].
Besides being targets of N-linked glycosylation which may assist in calnexin and
calreticulin associated quality control cycles [13], the pro region affects protein
trafficking at other stages of the secretory pathway. Insulin like growth factor is
inefficiently translocated into the ER without the pro region even when the pre region is
fully intact [14]. In addition work has identified amino acids that are necessary for
Erv29p-dependent protein sorting into COPII vesicles for ER to Golgi transport.
Mutations in the 139, L42, and V52 residues significantly impact COPII packaging in
vitro and also effect MFalp processing in vivo [15]. Furthermore, the Kex2 cleavage of
alpha factor pro as a leader of insulin precursor affects the balance between surface and
vacuolar targeting [16].
The alpha factor leader peptide has been used as a prepro sequence to direct a
variety of different proteins in addition to insulin precursor not only in S. cerevisiae but
in S. pombe, P. pastoris, as well as mammalian cells [17-19]. Interestingly, the leader
peptide has varying levels of success depending on the protein being directed. The leader
sequence fails to direct the secretion of GFP in S. pombe [17] but is relatively good at
secreting human lysozyme in comparison to other leader sequences in P. pastoris [18].
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Host differences aside, the success of a particular leader sequence in directing the
secretion of a protein of interest seems to depend a good deal on the protein in question.
In the following set of experiments, the yeast MFalpp is used as a basis to create
a mutagenized library of leader sequences. These leaders are then screened for improved
FLAG-4m5.3 secretion by way of the Cell Surface Secretion Assay described in Chapter
3. The isolated leader sequences successfully enhance the secretion of 4m5.3 in S.
cerevisiae. Furthermore, the leader sequences contain common trends in their
mutagenized residues indicating amino acid and motifs essential for trafficking 4m5.3 to
the yeast surface. These mutations also affect the intracellular processing of 4m5.3
secretory intermediates. The improved leaders are tested with other proteins including
other scFvs and are shown to stimulate the secretion of many of these proteins although
to different extents. The following work outlines a successful strategy for using a
directed evolution technique to generate hyper-secreting clones and is the first instance of
a large mutagenic prepro library being screened for better secretion. Indeed, this is the
first time flow cytometry has been used in the screening of a library for enhanced protein
secretion in yeast and suggests a new method for screening large libraries quickly with
greater adherence to industrial fermentation.
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4.2 Experimental Protocol
4.2.1 Alpha Factor Prepro Library Construction
For the creation of the alpha factor prepro library, the alpha factor prepro region
was PCR amplified directly from yeast genomic DNA supplied by a zymoprep (Zymo
Research, Orange, CA) of 10 OD600 of the yeast strain BJ5464a resuspended in 300 p1
Buffer TE. Sequences for the PCR primers (Alpha-pp-f and Alpha-pp-r) are given in
Appendix 2.6. The PCR product was then subcloned behind the galactose promoter in
the plasmid pRSD1.3SphI using the restriction enzymes SphI and NheI (New England
Biolabs, Beverly, MA) to create WTappD1.3. The FLAG-tagged alpha prepro 4m5.3
construct was created by PCR amplifying the prepro region using Alpha-pp-f and alpha-
pp-flag-r primers which introduced a flag tag behind the prepro region. This PCR
product was ligated into WTappD1.3 creating WTappFD 1.3. The 4m5.3 gene was
inserted into the construct by subcloning it from pRSFlag4m5.3 using the enzymes NheI
and XhoI thus creating the construct WTappF4m5.3 (sequence in Appendix 2.4) that is
marked with a tryptophan auxotrophy gene.
The PCR mutagenesis and library transformation was performed according to
Colby et. al. (2004), and a detailed protocol can be found in Appendix 2. Briefly, sixteen
micrograms of the acceptor vector WTappF4m5.3 was digested with the enzymes SphI
and NheI followed by gel purification. The library insert was created by PCR
amplification of the alpha factor prepro from WTappF4m5.3 using the nucleotide analogs
dPTP and 8-oxo-dGTP. Mutagenesis levels were adjusted by varying the nucleotide
analog concentration in the PCR reaction (2 ipM, 20 pM, 200 pM) and by varying the
number of PCR cycles (5 to 20). Transformation was accomplished by transforming 1 gg
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of acceptor vector and 5 gtg of insert PCR product into the yeast BJ5464a using five
electroporation shocks of 50 ll (1x10 8) cells. The transformants were inoculated into 1 L
of SD-CAA+40 mg/L uracil and passaged repeatedly. The transformation yielded 1x10 8
transformants as determined by plating dilutions. A library of unmutagenized alpha
factor prepro leaders was similarly transformed to serve as a negative control for the
prevention of leader-independent secretory improvement.
4.2.2 Library Screening
For screening the library was grown to saturation in SD-CAA + uracil and then
induced for ten to twelve hours in YPG/BSA. After induction a number of cells
sufficient to cover the library diversity was taken and labeled with NHS-PEG-fluorescein
(3.5 kDa) as described in Chapter 3. These cells were then placed in a YPG/PEG
solution and incubated overnight (-10 hours) in a static culture at 300 C. The cells were
washed with PBS/BSA/fluorescein and labeled with M2 anti-FLAG antibody (Sigma, St.
Louis, MO) followed by goat anti-mouse PE-Alexa6 10 conjugated secondary antibody
(Invitrogen, Chicago, IL ). The cells were sorted into PBS/BSA/penicillin-streptomycin
on a MoFlo or FACSaria FACS machine. Gates were initially drawn rather liberally
(~10% of the double positive population) but became more stringent (-0.5% of the
double positive population) as the library size diminished with more sorts. At each sort,
the progress of the selection was monitored by analyzing library supernatant in the
fluorescein quench titration assay described in Chapter 3 and Appendix 1. Selection
continued (-five rounds) until significant improvement in 4m5.3 secretion was observed
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for the mutagenized library relative to the wild-type. At this point the library was plated
on SD-CAA and individual clones were picked for analysis.
4.2.3 Isolated Mutant Characterization
Clones selected from the plated library were inoculated into SD-CAA + uracil and
then induced at saturation overnight in YPG/BSA. 500 pl of supernatant from the
induced cultures were analyzed in 3 mL of buffer using the fluorescein quench titration
assay. Plasmids from clones exhibiting significant secretory improvement over wild-type
transformants were removed using the Zymoprep Yeast Mini-prep Kit and transformed
into XL-1 Blue for amplification (Stratagene, Carlsbad, CA). A pool of clones collected
from the plate but not individually analyzed were also zymoprepped and transformed.
Prepro sequences were determined using the pp-Seq primer (Appendix 2.6). In the
meantime, the plasmids were retransformed into fresh BJ5464a to ensure that the
secretory improvement was due to the leader and not an exogenous host factor.
Transformants were grown, induced and assayed for 4m5.3 secretion as described above.
4.2.4 Site-Directed Mutagenesis
Site-directed mutagenesis was performed by PCR through the use of primers
containing point mutations. Briefly, primers carrying selected point mutations were used
to amplify the entire appF4m5.3 construct. The product was treated with the restriction
enzyme DpnI that selectively cuts methylated DNA thus destroying E. coli transcribed,
unmutagenized template. The digested DNA was then transformed into XL-1 Blue. The
V22A mutation in the wild-type leader was performed using the primers wtV22aQCt and
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wtV22AQCb. The A22V mutation in the alpha factor S4 study was introduced using
primers S4A22Vqcl and S4A22Vqc2. Similarly, the mutagenic primers in the alpha
prepro 8 experiments were #8A22Vqcl and #8A22Vqc2. The mutagenized products
were sequenced to ensure that the primers introduced the proper mutation. The prepro
leader sequence was then subcloned into new WTappF4m5.3 using an SphI and XhoI
digestion to ensure that there were no mutations in the backbone part of the vector that
could cause growth or replication defects. Site directed mutagenesis on the LLFI motif
was performed in a similar manner. The LSST motif on clone 8 was changed to LLFI
using the 8phobf and 8phobr primers. The motif was changed to SSST using the primers
8SSSTf and 8SSSTr. Finally, the residues were changed to LEDE using the 8polarf and
8polarr primers. The L55 residue was also targeting using site-directed mutagenesis with
primers L55FQC. The F48 residue was changed to a serine with F48SCQ primers, and
mutants were subcloned into the new vector as described above. Primer sequences are
given in Appendix 2.6.
4.2.5 Intracellular Western Blots
Intracellular forms of 4m5.3 were detected by Western blots of cell lysate. The
cells were induced in YPG/PBS for fourteen hours, centrifuged, and then resuspended in
100 .l TCA extraction buffer plus protease inhibitor. Cells were added to 1.5 ml vials
containing -600 pl of glass beads and 100 pll TCA and beaten with 2 50 second bursts on
a bead beater with one minute on ice between bursts. The lysate was withdrawn from the
beads and spun down at 12,000 rpm for five minutes. The supernatant was discarded and
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protein resuspended in 100 ld TCA resuspension buffer and boiled for five minutes. A
detailed protocol including reagent recipes is given in Appendix 1.7.
Deglycosylation was performed by boiling 17 gl of the protein in 2 gl of
denaturation buffer (New England Biolabs) for ten minutes. After denaturation 2 tl of
Buffer G5 was added to the solution followed by 3 tl of Endo Hf, and the protein was
incubated at 370C for 1.5 hours. After incubation 3 1l of glycerol loading buffer was
added to the sample and the protein was separated on a 4-12% Bis-glycine gradient gel
(Invitrogen). The protein was transferred to a nitrocellulose membrane as previously
described, and the 4m5.3 was detected using the anti-FLAG HRP conjugated antibody
(dilution 1:4000, Sigma). An antibody to PGK1 (1:500 dilution) followed by a 1:1000
dilution of goat anti-mouse HRP conjugate antibody was used as a loading control. The
Western was imaged using the FluorES phosphorescence imager (BioRad).
4.2.6 Mutant Leader Direction of Other Heterologous Proteins
To test the generality of the leader-derived improvement, the mutant prepros 8
and S4 were placed in front of a variety of heterologous genes. In general the genes for
the proteins to be expressed, IL-2 (Q126R), D1.3, 4m5.3, and disulfide stabilized sm3e
were amplified using primers containing flanking NheI and XhoI sites. The resulting
products were ligated into 8appF4m5.3 or S4appF4m5.3 following an NheI and XhoI
digestion. The constructs were then transformed into BJ5464a, inoculated into SD-CAA
+ uracil, induced in YPG/BSA for twenty-four hours then tested using an anti-FLAG
Western blot or fluorescein quench titration where applicable.
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4.2.7 Construction of IgG Vectors
The heavy chain was amplified by PCR from vector 6-23 IgG (Andy Yeung's thesis)
introducing Mlul and XhoI sites on the 5' and 3' ends respectively. The NheI site on
WTappD1.3/pRS314 was mutated to an MluI site to accommodate the subcloning of the
PCR product into the yeast vector. The light chain was amplified from 6-23 IgG using
primers introducing a 5' NheI site and a 3' XhoI site. The light chain was then cloned
into a yeast secretion vector by ligating it behind the alpha prepro region in
WTappF4m5.3/pRS316 with an NheI and XhoI digestion. The 4m5.3 variable light
chain was amplified from WTappF4m5.3 using primers introducing NheI and BswI sites
and the subcloned into the light chain yeast vector to create WTapp4mIgGLC. The
variable heavy chain was also amplified from WTsppF4m5.3 using primers that
introduced MluI and NheI sites on the 5' and 3' ends respectively. The variable heavy
chain was then subcloned into the heavy chain secretion vector to create WTapp4IgGHC.
The app8 and appS4 promoters were then added in using an SphI to NheI digest in the
case of the light chain or an SphI to MluI leader PCR followed by a ligation in the case of
the heavy chain. Vector sequences can be found in Appendix 2.5.
4.2.8 Fluorescence Microscopy of Internalized 4m5.3
The intracellular microscopy was performed using the same protocol outlined in Chapter
2. The cells were fixed, permeabilized, and then labeled with M2 anti-flag antibody with
a goat anti-mouse FITC secondary antibody.
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4.3 Results
4.3.1 Alpha Factor Prepro Library Screening
One approach to finding improved heterologous protein secretors is to engineer an
improved leader sequence to direct the secretion of the recombinant protein. The alpha
mating factor prepro leader sequence has often been used to direct the secretion of a
variety of proteins in both S. cerevisiae and P. pastoris. In the following experiments we
use the wild-type alpha factor prepro to create a library of mutagenized leader sequences
and then screen the library for improved secretion of 4m5.3 using the CeSSA. The alpha
factor prepro sequence was amplified from the strain BJ5464a and then mutagenized
using error-prone mutagenesis with nucleotide analogs. The PCR products were
transformed into yeast with tryptophan-marked acceptor vector where they homologously
recombined to yield a library of lxl08 transformants. A library of unmutagenized
prepro was also transformed to serve as a screening negative control. The library was
grown in SD-CAA and then induced for ten hours at saturation in phosphate buffered
YPG/BSA. Cells from the induced culture were taken, labeled with NHS-PEG-
fluorescein, and incubated using the Cell Surface Secretion Assay as described in Chapter
3. After washing, the cells were labeled with an anti-FLAG antibody followed by a PE-
Alexa610 conjugated secondary antibody. The library was sorted repeatedly until a
significant improvement in secretion was seen (Figure 4.3.1). The nonmutagenized
library was sorted in a similar fashion.
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Figure 4.3.1 Progressive Enrichment of Alpha Factor Prepro Library. A
mutagenized library of alpha factor prepro directing the secretion of FLAG-tagged 4m5.3
was sorted for better secretion using CeSSA. An unmutagenized (WT) leader was also
sorted. The mutated library shows a higher rate of enrichment than its WT counterpart.
The mutagenized library showed gradual improvements in secretion over the
course of the screening as measured by fluorescein quench titration. The wild-type
library also began to show improvement most likely owing to the presence of
spontaneous mutations in the leader or more probably the host that resulted in improved
secretion. After sufficient rounds of selection, the library was plated, the mutant leader
peptides in individual clones were sequenced, and the isolated constructs were
transformed into fresh cells. All of the clones analyzed showed significant 4m5.3
secretory improvement over the wild-type leader sequence and most exhibited
improvement over an alternative synthetic prepro leader sequence. Interestingly, the
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improved secretion was concomitant with reduced growth rate causing an exaggerated
increase in secretion on a per cell basis (Figure 4.3.2).
Figure 4.3.2 4m5.3 Secretion from Isolated Alpha Factor Prepro Mutants. Mutant
prepro leader sequences improved FLAG-4m5.3 secretion anywhere from ten to twenty-
two fold per cell over the WT leader sequence and up to two and half fold over the
synthetic prepro leader peptide on a per cell basis. Error bars indicate one standard
deviation
4.3.2 Isolated Clones
The sequences of the isolated prepro regions were analyzed for common elements that
might be responsible for the improvement in secretion. Sequences of four of the best
secretors and their corresponding secretory competences are given in Figure 4.3.3 A and
B respectively.
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VNTTTEDETAQI AEAVIGYLDLEGDFDVAVL FS STNNGLLF IASIAAKEEGVQDKR-....
ANTTTEDETAQI AEAVIDYSDLEGDFDAAAL LSNSTNNGLSSTNTTSIAAKEEGVQLDKR- .....
ANTTAEDETAQI AEAVIGYLGLEGDSDVAAL LSDSTNNGSLSTNTTIASIAAKEEGVQLDKR-.....
ANTTTEDETAQI AEAVIGYLDSEGDSDVAVL FSNSTNNGLSFINTTIASIAAKEEGVQLDKR-....
ANTTTEGETAQT AEAVIGYRDLEGDFDVAVL F, NSTNNGLLFTNTTTASIAAKEEGVQLDKR-......
Figure 4.3.3 Sequence of Mutant Prepro Regions and Their Resulting Impact. The
sequences of four selected leader mutants and their corresponding glycosylation and
cleavage sites are given in (A). These mutants all exhibit a V22A mutation as well as a
trend away from the LLFI motif before the third glycosylation site in favor of more polar
residues. These sequences are representative of the other isolated clones, and mutations
from WT are underlined. (B) The 4m5.3 improvement resulting from the mutations is
shown with one standard deviation indicated.
The sequences show a few common trends. One of the most striking similarities
is an almost universal mutation of the 2 2nd residue from valine to alanine. This
substitution would seem to be a conservative change to a slightly less bulky and
hydrophobic residue but perhaps it is significant that it arises just after the signal
peptidase cleavage site and just before the first N-linked glycosylation site. Perhaps this
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mutation accelerates the rate at which signal peptidase is able to cleave the translocating
polypeptide or the rate and efficiency upon which the first N-linked sugar moiety is
attached. To test the necessity of this mutation in effecting the secretory increase, a
mutagenic cycle of the wild-type and two of the enriched clones, clones 8 and S4, was
made (Figure 4.3.4A). The analysis shows that the mutation is essential to although not
wholly responsible for the improvement in 4m5.3 secretion (Figure 4.3.4B).
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Figure 4.3.4 The Effect of the V22A Mutation. A cycle of mutations on the 2 2nd
residue was preformed. The wild-type alpha factor leader underwent a V22A mutation
while the improved leader sequences alpha prepro 8 and alpha prepro S4 underwent a
V22A mutation back to the wild-type residue (A). The V22A mutation seems to
negatively impact secretion in a WT framework yet is necessary for maximum secretory
improvement in the isolated clones (B). The error bars indicate one standard deviation.
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Interestingly, the V22A mutation had a mild negative impact on wild-type leader
secretion levels suggesting that this mutation is dependent on other mutations in the
leader sequence to achieve its full effect
Although the V22A mutation accounts for half of the secretory improvement, the
A22V clones still secrete at higher levels than the wild-type construct. Another common
theme that may contribute to the secretory increase is the mutation of the hydrophobic
LLFI motif at the 63rd residue just N-terminal to the third glycosylation site to residues
that are more polar (Figure 4.3.5). Furthermore, there seems to be a negative correlation
between the hydrophobicity of this region and improvement in 4m5.3 secretion.
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To test the impact of polarity at this motif on secretion, mutations were made to
this sequence in the context of clone 8. To do this analysis, the LSST motif in clone 8
was mutated to wild-type LLFI, a more polar LEDE, or to a completely polar SSST
(Figure 4.3.6). The results show that changing LSST to LLFI in clone 8 had a marginal
negative impact on 4m5.3 secretion (Figure 4.3.6B). Furthermore, the SSST mutation
also had a negative impact indicating the necessity of some hydrophobic presence in that
motif. In addition the LEDE mutation maintained secretion at clone 8 levels indicating
perhaps a preference against hydrophobic residues rather than a preference for polar ones.
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Figure 4.3.6 Secretion with Mutagenized LLFI Motif. The LSST motif stretching
from the 63 rd to the 66t residues in clone 8 was mutagenized to introduce a more
hydrophobic (WT) sequence (LLFI), an even more polar sequence (LEDE), or a totally
polar sequence (SSST), (A). The hydrophobic patch has a small negative effect on 4m5.3
secretion that can be reversed by the addition of even large acidic side chains. The SSST
mutation also had a slightly negative effect.
The experiments presented to this point indicate that the V22A mutation is
responsible for perhaps half of the improvement with the polarity of the LLFI motif also
playing a small role. In addition to these two conserved areas of mutation, there is an
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additional theme that concerns the conservation of the phenylalanine residues in the 48th
and 55t positions just N-terminal to the second N-linked glycosylation site. In all of the
mutants examined, there was a direct mutation, usually F48S or F55L, or a disrupting
mutation (mutations to proline) in an adjacent residue that would seem to suggest that
these two residues play a role in secretory improvement. To test the importance of these
residues, L55 in alpha prepro 8 was reverted back to the wild-type Phe residue. In an
attempt to enhance secretion, the F48 residue was changed to a serine which was found at
this position in some of the other mutants (4.3.7). The cumulative effect of all of the
mutations discussed up to this point was also tested.
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Figure 4.3.7 Mutagenesis of Phe48 and Phe55 Residues. The L55 residue in the app8
mutant leader was mutagenized to Phe. Alternatively, the F48 residue was mutagenized
to Ser (A). The L55F mutation has a minimal negative effect on secretion and the F48S
mutation has an even greater negative effect (B). The cumulative effect of all three
families of mutations that have been discussed is also shown.
The L55F mutation has a slight negative effect on secretion suggesting that a
mutation to this residue is not a major contributor to the secretory enhancement seen with
the mutant leaders. Surprisingly, the F48S mutation has an even larger negative impact
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on secretion. Perhaps one of the phenylalanine residues is necessary for trafficking or
stability.
To determine if these mutations had any noticeable effect on intracellular protein
trafficking, Western blots of the lysate of secreting cells were performed (Figure 4.3.8A).
These blots can be compared to a summary of important mutations tested thus far
(4.3.8B).
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Figure 4.3.8 Effects of Selected Mutations on Intracellular Trafficking and
Secretion. An intracellular Western blot reveals three kinds of intracellular secretory
intermediates. One of two glycosylated forms consistent with the molecular weight of
prepro 4m5.3 or pro 4m5.3 is retained to varying degrees in all of the clones.
Additionally a form consistent with mature 4m5.3 is also retained. Only the mature form
of 4m5.3 is secreted from the wild-type clone (A). A summary of the secretory
competences of site-directed mutations (B).
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One of two types of glycosylated high molecular weight intermediate is present in
each of the clones. It seems that the higher weight form (intermediate 1) is more likely to
be present in the isolated mutants despite the lower weight form (intermediate 2) being
present in the wild-type. Furthermore, it appears that the lower weight form is favored in
clones with a more hydrophobic LLFI motif, specifically regarding the isoleucine residue
immediately adjacent to the third glycosylation site. This hydrophobicity/retained
intermediate correlation is dominant over the other mutations. If this residue remains an
isoleucine even with other surrounding polar mutations, app3, a downward shift in
apparent molecular weight is seen. If this single residue is changed to a threonine, even
when surrounded by other hydrophobic residues, the intermediate remains in a higher
molecular weight form, app 10. The two bands could be prepro and pro leader meaning
that the LLFI motif may have an impact on signal peptidase cleavage. To highlight the
differences in the amount of retained protein between the clones, blot density was
normalized to a PGK1 loading control (not shown) and compared with the wild-type.
The results of the comparison are given in Figure 4.3.9.
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BFigure 4.3.9 Levels of Intracellular Protein in Selected Clones and Mutants. The
levels of the two intermediates uncleaved by Kex2 were normalized to a PGK1 loading
control and compared to the retention in the WT leader (A). The intracellular
concentration of the mature form was analyzed in a similar manner (B).
Figure 4.3.9 shows that, in general, there are less unprocessed and mature
intracellular protein accumulation in the selected mutants than in the wild-type leader
suggesting that intracellular accumulation of protein is bad for secretion. Paradoxically,
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the A22V mutation which is quite harmful to secretion in the alpha prepro 8 leader has
the least amount of un-Kex2 processed intracellular protein accumulation of all. It is also
apparent that there is not as much variability in the mature retained form as in the
unprocessed intermediate. As has been discussed earlier, heterologous protein is often
trafficked to the vacuole for degradation. The mature protein here has been traveled
through the trans-Golgi as evidenced by Kex2 cleavage, so this form may be in the
vacuole where it is not degraded due to the pep4/prb deletion. To see where this protein
is localized, indirect immunofluorescence microscopy was performed on the app8
expressing clone (Figure 4.3.10). The app8 leader was chosen because it contains a good
deal of mature 4m5.3 but very little of the higher molecular weight intermediate.
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Figure 4.3.10 Indirect Immunofluorescence of app8 directed 4m5.3. 4m5.3 was
detected with a fluorescently labeled antibody in fixed and permeabilized secreting cells.
The protein localizes in a large, confined area consistent with vacuolar localization.
The 4m5.3 in the secreting cells is localized to a large organelle that is consistent with
vacuolar structure although without a co-localizing vacuolar antibody, it is difficult to be
sure.
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4.3.3 Mutant Leaders and Secretion of Other (non-4m5.3) Proteins
After demonstrating the significant improvement the mutant leaders confer onto
FLAG-4m5.3 secretion, the secretion of other proteins was directed using the two best
mutant leaders: alpha factor prepro clones 8 and S4 (Figure 4.3.11). To test to what
extent the FLAG tag plays a role in secretory improvement, a 4m5.3 construct lacking the
FLAG tag was synthesized and secreted. This test showed that the FLAG tag had very
little effect on 4m5.3 secretion and showed similar levels of leader-derived improvement.
Two non-4m5.3 scFvs, FLAG-D1.3 and a disulfide stabilized version of FLAG-sm3e,
were also tested using the new leaders. sm3e showed significant secretory improvement
(more than three fold) over the WT alpha factor prepro directed constructs. The effect on
D1.3 was positive but marginal. Perhaps processing bottlenecks are different for DI.3
than for the other proteins tested. To test general applicability of these leader peptides to
proteins not containing the f3-sheet rich scFv fold, a mutant of the alpha-helix containing
heterologous protein IL-2, IL-2 (Q126R), was tested using the improved leaders.
Surprisingly, the leaders conferred a three to four fold improvement on the secretion of
this FLAG-tagged protein suggesting that improvement may be extrapolated to proteins
without significant homology to single-chain antibodies.
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Figure 4.3.11 Protein Secretion Utilizing Engineered Alpha Factor Prepros app8
and appS4. The improved leader sequence stimulates the secretion of a variety of scFv's
and proteins. The leader improved secretion anywhere from 1.5 to 14-fold with the most
improvement being observed for FLAG-4m5.3, the construct that was used for the
screen.
One industrially and academically important protein that is produced poorly in
yeast is the whole IgG molecule. Although whole IgGs have been produced with some
success in Pichia, very little (-50 pg/L) has been reported in S. cerevisiae [20]. With this
in mind, the heavy and light chains of a 4m5.3 mouse/human chimera antibody were
placed behind the WT, app8, and appS4 leader sequences and secreted into the
supernatant. The supernatant was then purified on a FLAG resin column, and the results
for the app8 production are given in Figure 4.3.12.
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Figure 4.3.12 Expression of IgG. A human/mouse 4m5.3 IgGi chimera was expressed
behind the app8 promoter. After three days of growth, the supernatant was purified on a
FLAG resin column and analyzed by Western blot. The blot shows full-length, DTT, and
EndoH (un-EndoH treated protein not shown) sensitive IgG. A fluorescein quench
titration confirms its functionality.
4.3.4 Further Expression Improvement
After the mutant leaders were shown to stimulate the production of many types of
proteins including whole IgG, the leaders were combined with other mutations that have
been shown to be advantageous in the past. To boost secretion even further, 4m5.3 was
expressed from an additional CEN plasmid transformed into cells with and without an
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extra copy of PDI. The extra plasmid as well as the PDI integration improved 4m5.3
secretion to thirty times that of the wild-type leader alone (Figure 4.3.13). Because the
heavy and light chains on the IgG molecule are expressed from different plasmids, it was
thought that stably integrating the constructs into the chromosomes of a PDI
overexpressing strain of yeast would improve secretion further. The resulting strain
secreted around 8 mg/L of IgG as measured by the functional assay. This figure is just an
estimate as the bivalency of the IgG raises the apparent concentration; however,
reformatting the scFv into an IgG might negatively impact the intrinsic affinity.
However, it can be estimated that IgG secretion is around 4 mg/L at the least, and this
number has been verified with quantitative Western blots.
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Figure 4.3.13 Additional 4m5.3 and IgG Expression Improvement. The improved
secretory leader as well as additional copies of the CEN plasmid and PDI stimulate a
thirty-fold increase in 4m5.3 scFv secretion over the wild-type leader alone. A similar
improvement is seen for the secretion of a 4m5.3 whole IgG.
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After the successful isolation of improved secretory leader regions, other types of
libraries were screened in conjunction with the alpha factor prepro 8 sequence. In
addition to another round of mutagenesis on the leader sequences, screens utilizing S.
cerevisiae cDNA and deletion libraries were examined. The second round of
mutagenesis on the secretory leader proved ineffectual as no improvement in secretion
was seen over multiple rounds of selection. However, iterative improvement in protein
secretion in the deletion library was observed. Clones isolated from this library were
plated and checked for secretion and were found to confer a 2.5 to 3-fold improvement
over WT in 4m5.3 secreting cells. The mutations in these cells were identified as being
deletions in YBR232c-an uncharacterized ORF, YJL105w-another uncharacterized ORF
containing a SET domain commonly found in histone acetylating proteins, and APM4-a
clathrin coated vesicle protein. The most intriguing isolate is the last clone indicating a
bottleneck due to Golgi-localized vesicle packaging. However, when fresh clones were
taken from a frozen stock and transformed with 4m5.3, they failed to reproduce the
results of the isolates. This failure could be due to additional mutations in the enriched
cells that are necessary for the effects of the directed deletion to be felt.
The cDNA library similarly showed improvement over multiple rounds of sorting.
However, when the cDNAs were isolated and analyzed it was found that they were
additional copies of 4m5.3. It appears gene conversion occurred between the 4m5.3
expression vector and the cDNA vector which share significant homology in the
galactose promoter as well as the backbone. This phenomenon was also observed in
selections for synthetic prepro directed 4m5.3 secretion in conjunction with libraries of
BPTI secretory mutants, Hac' mutants, and Taf and Sptl 5 mutants. However, as bleak as
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these results may appear, it does suggest that expressing multiple copies of 4m5.3 in the
same cell might be a productive method for improving secretion, which was proved to be
the case in later experiments.
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4.4 Conclusions
A randomly mutagenized alpha factor prepro library was generated and screened
for improved protein secretion. This library showed higher rates of maturation over a
population of cells containing the wild-type leader region only. The use of the CeSS
Assay as a means to isolate better secreting clones has been proven to be a valid
screening system as all of the clones isolated from the screen exhibited improved 4m5.3
secretion over the wild-type leader region.
Within this group of isolated clones, there is a heterogeneous population of
leaders exhibiting levels of improvement from ten to twenty-fold. However, within this
varied group of improved leader sequences, there lie some similarities. The most
prominent comparison is a ubiquitous V22A mutation. Clones lacking this mutation
show a fifty percent drop in their secretory improvement suggesting that this mutation is
necessary although not sufficient for the secretory effects. In fact, changing this residue
in wild-type cells negatively impacts secretion. The clearest intracellular effect of the
V22A mutation is its impact on prolonging the unprocessed prepro half-life and a
contribution to elevated levels of retained mature form. When considering the material
balance, a good hypothesis might be that the V22A mutation helps the mutant leader
avoid protein degradation in the vacuole by prolonging the persistence of the unprocessed
intermediate: allowing it to fold properly. Because only fully processed protein is found
in the supernatant, it does not appear that a V22A-mediated disruption of Kex2 cleavage
is responsible for the improvement in secretion. At any rate it is apparent that the V22A
mutation acts in concert with the other mutations to effect a secretory improvement.
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Perhaps the other mutations needed to improve secretion have a destabilizing effect that
is counteracted by the V22A mutation.
One potential interaction partner are the residues replacing the LLFI motif.
Mutagenesis at this site suggests that the LLFI motif is slightly disfavored in the context
of the other mutations in clone 8. Other more bulky and polar side chains are allowed at
this region but do not confer any increased advantage over the selected LSST. Indeed,
this stretch of amino acids shows a good deal of heterogeneity in the selected clones as
many of the mutants show just one mutation in this region and one clone did not show
any mutations at all. The most important residue seems to be the isoleucine residue just
N-terminal to the glycosylation site. Mutating this residue to a threonine causes the
intracellular form of un-Kex2 cleaved intermediate to shift to a higher weight consistent
with the retained forms of the improved mutants. Intracellular app3 which is an
improved mutant yet retains the isoleucine appears as a lower molecular weight
intermediate: although it remains a strong secretor. The most obvious explanation is that
polar residues at this motif negatively affect signal peptidase cleavage resulting in a
higher molecular weight form. This prepro form is apparently fully translocated,
processed, glycosylated, and beneficial to secretory trafficking perhaps by stabilizing the
folding protein, but it does not increase intermediate half-life. Clearly, this mutation is
important to protein trafficking but does not significantly affect overall secretion.
Now that some of the details of the intracellular trafficking have been uncovered,
it is now our task to make a hypothesis about the source of the secretory improvement.
As a first step, we can determine the amount of intracellular protein that actually gets
secreted by comparing amounts of secreted and retained protein via quantitative Western
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blots. Assuming that the mature intracellular form is terminally localized to the vacuole
and that the cell makes a binary sorting decision between the surface and the vacuole at
the late Golgi stage, we find that, at most, the cell secretes about 25% of the protein that
passes through the trans-Golgi when secretion is directed by the wild-type prepro leader.
This is an upper limit estimation as there is probably still some proteolytic activity in the
vacuole and some protein may be trafficked back to the ER from the late Golgi. A
measure of the distribution in wild-type, app8, and two of the app8 mutants is given in
Figure 4.4.1.
Figure 4.4.1 Distribution of Intracellular and Secreted Protein. Total 4m5.3
accumulation in arbitrary units is shown on the y-axis. The percentage of detected
protein found in a particular form (secreted, mature, or high molecular weight
intermediate) is also given.
From Figure 4.4.1 it can be seen that the leader mutations affect both total
detectable protein flux as well as the distribution of detectable protein. The V22A
136
mutation in app8 seems to cause enrichment in total protein as well as a re-distribution of
late-secretory pathway traffic favoring the surface. The LLFI motif mainly seems to
affect total protein flux but not distribution. It should be noted that as the mature and
secreted forms of 4m5.3 can be thought of as integrations of protein traffic over the
course of the induction, it is quite probable that the higher molecular weight form is a
transient intermediate that is continuously turned over through the course of induction.
Consequently, although the secreted and mature forms can be thought of as a total and
can be directly compared, the intermediate is just a snapshot of what is going on in the
cell at the time of lysis and can only be compared to other intermediates. However, these
data are still useful because it gives the observer a snapshot of what is going on inside the
cell at a particular time. Clearly, some mutations affect the instantaneous flux of protein
in the intermediate state.
From these experiments on can make a tentative hypothesis about how the
specific mutations studied are affecting secretion. It seems that the V22A mutation
increases the total flux through the secretory pathway within the context of the other app8
mutations. Furthermore, it increases the amount of protein that is found in the
intermediate form. This increased retention time might help the protein to better fold
making it more likely to be sorted to the surface by a VPS. The data also show that the
V22A mutation affects the distribution of the mature form of 4m5.3. The LLFI mutations
do not affect protein distribution but do affect total flux. Perhaps the unprocessed, higher
molecular weight form has a stabilizing effect on folding. An outline of a potential
hypothesis for mutant leader-induced secretory alterations given the data here is given in
Figure 4.4.2.
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Figure 4.4.2 Changes in Trafficking of Mutant Leaders. The mutant leaders seem to
confer a net change in protein traffic from the vacuole to the surface as well as an
increase in total protein flux. The LLFI motif affects intermediate size that suggests that
it plays a role in signal peptidase cleavage with retained pre regions being advantageous
for secretion. The V22A mutation results in a net increase in total protein as well as a
redistribution of protein from the retained mature form to the surface.
Another interesting analysis on the selected clones is to determine what residues
from the wild-type leader were retained in the improved leader sequences. In general
there were few mutations made to the pre region of the leader, and when these mutations
were made, they were usually relatively conservative valine to alanine or leucine to
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valine conversions. Only one mutation was observed collectively in the pre regions of
the alpha prepro 8 and S4 leaders discussed in detail here. With the exception of the
V22A mutation, the hydrophobic patch surrounding the signal peptidase cleavage site
was strongly conserved as was the overall positive charge on the pre peptide. The first
hydrophilic stretch of the pro region was also strongly conserved. At most only one
mutation was found in this region for the most productive clones suggesting that this
region is important for protein trafficking. The C-terminal portion of the leader was also
strongly conserved. In fact, none of the clones exhibited any mutations from the 7 3rd
isoleucine residue to the end of the Kex2 cleavage site at the 86dh residue. This feature
shows a strong preference for maintaining wild-type sequence as it must be necessary for
proper protein trafficking. For the most part, N-linked glycosylation sites were
conserved. However, in clone S4, one of the most productive clones, the second
glycosylation site was deleted all together by an N57D mutation. Moreover, the site was
re-introduced just downstream when the asparagine at position 61 was made a
glycosylation site by a L63S mutation. This phenomenon was also observed in the highly
secreting alpha prepro 9 clone. These mutants suggest that while the number of N-linked
glycosylations may be important, there is some leniency as to exactly where these sites
are located. Interestingly the putative COPII vesicle sorting sequence 139, L42, V52 do
not seem to be strongly conserved in the mutants as clone 8 contains mutations in two of
the three residues.
In addition to improving the secretion of FLAG-tagged 4m5.3 and providing
information as to the importance of certain prepro residues in secretory trafficking, the
isolated alpha factor prepro leader sequences stimulate the secretion of many other
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proteins. Perhaps not surprisingly, the leaders stimulate the secretion of other single-
chain antibodies whether they contain the FLAG tag or not. One example where little
improvement was seen was for the scFv D1.3. This protein may possess a processing
bottleneck that cannot be relieved by using the mutagenized leader sequences alone.
Perhaps it is not insignificant that co-expression of surface displayed BPTI as discussed
in Chapter 2 imparted a large improvement in D1.3 secretion but not much change in
4m5.3 secretion. These two methods for improving secretion may be addressing two
different processing needs that may likewise be differently significant to individual
proteins. The leader imparted secretory improvements in the IL-2 (Q126R) mutant as
well as the whole IgG show that these leader sequences can potentially be used for
production of numerous industrially and academically relevant proteins.
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Appendix 1: Protocols
A1.1 Yeast Transformation by Electroporation
(from Colby et. al., 2004)
DNA Preparation
1. Prepare insert vector such that flanking regions to gene have -50bp of homology
to acceptor vector (chromosomal target). Usually this is done through PCR.
You'll need about 10g of DNA per transformation. Maybe 40gg total (-20
100l PCR reactions).
2. Precipitate the DNA using Pellet Paint co-precipitant. Resuspend in -5 tl of Tris-
Cl or EB Buffer.
3. Prepare acceptor vector if necessary by cutting with appropriate restriction
enzymes. You'll need about Il g per transformation or about 5gtg. Precipitate
with Pellet Paint.
Preparation of Cells
This protocol is sufficient for six transformations using 60gtg of insert and 6jig of
acceptor vector.
1. Inoculate 100 ml of YPD to OD600 from overnight inoculum.
2. Grow cells about six hours at 300C to OD - 1.1 to 1.5.
3. Add 1 mL filtered DTT solution (IM Tris, pH 8.0, 2.5M DTT). Continue shaking
for an additional ten to twenty minutes.
4. Harvest cells by centrifugation in 50mL centrifuge tube at 40C and discard
supernatant. Wash with 25 mL room temperature E buffer (10 mM Tris, pH 7.5,
271 mM sucrose, 1 mM MgCl 2).
5. Spin down again and was once more in 2 mL E buffer.
6. Resuspend cells in final volume (cells + buffer) of 300 gil.
Electroporation
1. Mix 1 jg of vector with 9pg of insert and add 50 jil of competent yeast cells. Add
mixture to sterile 0.2-cm electroporation cuvette. Incubate 5 minutes on ice.
Prepare 1 cuvette for every 50 jil transformation
2. Set gene pulser to 25 pF (capacitance) and 0.54 kV (voltage).
3. Electropulse the cuvette until a "beep" is heard.
4. Immediately add 1 mL of room temperature YPD to cuvette and move cells and
media to 15 mL culture tube. Shake at 300C for 1 hour.
5. Spin down cells and inoculate into desired volume of selective media. Plate
dilutions to test transformation efficiency. Transformation efficiency is usually
around 106 transformants/jg insert.
Andy Rakestraw
May 5, 2006
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A1.2 Surface Display and Flow Cytometry
1. Grow cells (usually overnight) in SG-CAA or YPG. When ready for labeling,
collect 0.2 OD600 of cells.
2. Spin down cells and wash 1 time in 500 gl PBS/BSA (0.1% BSA).
3. Spin down cells and resuspend in 50 gl1 of primary label diluted into PBS/BSA.
Incubate between fifteen minutes and half an hour on ice depending on the
affinity of the label for the epitope you're detecting.
4. Spin down and wash with 500 il PBS/BSA
5. Resuspend in 50 jil of secondary label, and incubate 10 to 20 minutes on ice
(biotin/avidin -10 minutes, antibody/epitope -20 minutes or longer).
6. Wash once more in 500 gll PBS/BSA and resuspend in -300 pl PBS/BSA.
Transfer cells to flow cytometry tube.
Andy Rakestraw
May 5, 2006
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A1.3 Indirect Immunofluorescence Microscopy of Yeast Cells
Cell Fixing and Permeabilization
1. Induce protein expression through growth (usually overnight) in 5 mL SG-CAA
or YPG.
2. Add 500 •l of formaldehyde directly to the culture and shake additional 1.5 hours
at 300C.
3. Remove 1 OD600 of cells and wash twice in 1 mL PBS/0.5% Tween-20 (PBST).
4. Resuspend cells in 0.5 mL 50 ptg/mL zymolase diluted in PBST. (2 jil stock
zymolase for every 0.5mL of PBST). Incubate 20 minutes at 370 C. Do not
overincubate as proteolytic contaminants in the zymolase can ruin your sample.
5. Wash three times in 1 mL PBST. From this point, spin cells no faster than 6000
rpm to avoid breaking open the spheroplasts.
Cell Staining
1. Resuspend the cells in dilution of primary antibody(ies) in 20 jl of PBS/4%BSA.
(Use 10 Cgg/mL chicken anti-myc, 10 gg/mL M2 anti-flag, and 20 gg/mL 13D11
anti-vacuole membrane).
2. Incubate one hour at room temperature.
3. Wash one time in 500 •l PBS/BSA then incubate fifteen minutes in 500 11l
PBS/BSA.
4. Wash one more time in PBS/BSA then resuspend in secondary antibody diluted in
20 jtl PBS/BSA. (40 gg/mL of Alexa488-conjugated anti-chicken antibody, 10
gg/mL of goat-anti-mouse PE and lmg/mL Hoechst DNA stain).
5. Incubate one hour at room temperature in the dark. Wash and incubate in
PBS/BSA for fifteen minutes as described above.
6. Spin down, resuspend in -5 pl of PBS.
Slide Preparation
1. Wash slides and cover slips in watch glass with 1 M HCl for five minutes. Wash
with water and then wash with EtOH. Dry in fume hood on ChemWipes.
2. Add 20 pl poly-L-lysine to slide and let sit for 1 minute before aspirating off.
3. Wash poly-L-lysine spot with 3 washes of 20 pl PBS. Aspirate off each time.
4. Add 5 p.l of cells to lysine spot. Let sit for 1 minute and then aspirate off liquid.
5. Wash cells one time with 15 pll PBS.
6. Add 3 pl of mounting solution and attach cover slip. Apply nail polish to cement
slip to slide.
Andy Rakestraw
May 5, 2006
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A1.4 Cell Surface Secretion Assay
Cell Labeling
1. Induce protein expression for ten to twelve hours by growth in SG-CAA or YPG.
Remove 1 OD600 of cells.
2. Wash three times in 500 il of carbonate buffer pH 8.4 (4.2% NaHCO 3 and
0.034% NaCO3).
3. Resuspend cells in 10 gl 100 gg/gtl NHS-PEG-fluorescein (or NHS-PEG-biotin)
diluted into carbonate buffer. Solution will be very viscous and will need
frequent vortexing.
4. Incubate cells at room temperature for thirty minutes vortexing every ten minutes
(keep in dark if labeling with fluorescein).
5. Wash cell three times with 1 mL PBS/0.l%BSA.
6. For biotin labeling:
a. Resuspend cells in 20 gil 10mg/mL avidin dissolved in PBS and incubate
at room temperature for 20 minutes.
b. Wash as in PBS/BSA as described above and resuspend in the
biotinylated-protein of your choice. For D1.3 capture 30 gtl of biotin-
lysozyme was used. Incubate for 20 minutes at room temperature and
wash as described above.
Plate Preparation
*This step can be done while the cells are being labeled.
1. Make solution of 30 wt/v% polyethylene glycol (8 kDa) and YPG/BSA. (This
solution is 50% PEG by volume. i.e. use 5 ml of PEG powder and then add YPG
to total of 10 ml of solution.) You can accelerative dissolution by incubating
solution at 420C.
2. Filter sterilize the media. You will need -9mL for every 2 OD600 of cells. Add
labeled and washed cells to YPG/PEG (2 OD/9mL as described) and apply 9 mL
of suspension to 10x10 cm square sterile petri dish.
3. Rock dish back and forth until the bottom is completely covered. Get rid of any
large bubbles by aspirating them with a pipet. (Getting rid of bubbles is important
as they will eventually pop and cause the media to recede to the middle.
4. Incubate in a 300C incubator for an empirically determined amount of time (-11
hours for the alpha mating factor screening experiments).
Cell Washing and Labeling
1. After sufficient incubation, wash cells with 10 ml PBS/BSA. (If your secreted
protein has a fast off-rate, you may want to add competitor to the wash buffer.
This addition is not necessary for 4m5.3 secretion.)
2. Collect in a 50 mL conical and spin down cells (3500 rpm for 5 minutes.
3. Wash in 1 mL PBS/BSA and transfer to 1.5 ml tube. Wash twice more in 1 mL
PBS/BSA and then label with antibodies similarly to surface display.
Andy Rakestraw
May 5, 2006
146
A1.5 Fluorescein Quench Titration Assay
(adapted from Katerina Midelfort's Thesis)
1. Express 4m5.3 through growth in SG-CAA or YPG. Collect supernatant by
spinning down the cells.
2. Collect 0.5 mL supematant for the assay.
3. Add sample to 2.5 mL Assay Buffer, TBS (50 mM Tris, 150 mM NaCl pH 8.0)
4. Place in cuvette holder in Fluorescence Spectrophotometer
Settings:
a. Excitation: 494 nm, slit 2.5, filter auto
b. Emission: 517, slit 5.0, filter open (sometimes use a OG495 Melles Griot
yellow filter to keep excitation light from scattering into the detector.)
c. PMT: medium, average time: 0.2 seconds with 3 samples taken at each
point.
d. Temperature control set to 300C
5. Take initial reading.
6. Add fluorescein (most experiments use 10 gM fluorescein dissolved in TBS). I
usually start by adding in 3 gl increments. Wait five minutes and take a reading.
Wait an additional five minutes and take another reading. Keep waiting and
measuring until the same absorbance is reached for two readings in a row. Then,
add more fluorescein.
7. Repeat this process until the increase in signal with each addition is similar to the
increase seen for a negative control of supernatant lacking any 4m5.3.
8. Correct for the background and determine and derive a calibration curve by doing
the experiment in supernatant without fluorescein (as described above.)
9. Fit the data to the
expression:
data = c * 0.5 * q * (-(M((2 - q)/q) * F + Kd) + ((M - F + Kd)2 + 4 * Kd * F)0 5
where F is fluorescein concentration in the cuvette, M is 4m5.3 concentration in
the cuvette, q is the quench constant (0.95 for 4m5.3), and the Kd for 4m5.3 is 0.3
pM for 4m5.3. c is the slope of the line from the calibration curve.
10. You can find the 4m5.3 concentration by fitting that expression to the data and
finding an M value that gives the best fit.
Andy Rakestraw
May 5, 2006
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A1.6 TCA Precipitation of Intracellular Lysate
Adapted from Anne Robinson's protocol
1. Induce protein expression through growth in SG-CAA or YPG. Collect 4 OD600
of cells. Wash lx in 1 mL of PBS.
2. Spin down. (Cells can be stored at -200 C at this point).
3. Resuspend cells in 100 il TCA buffer plus protease inhibitors (lx Halt Cocktail,
or Complete protease cocktail.) Transfer to 1.5 mL screwcap vial containing 600
ll pre-washed glass beads and 100 tl 20% TCA. (You can wash beads in
Alconox, but be sure to try them thoroughly.)
4. Pulse beads and cells in bead beater for 2 50-second bursts resting for 1 minute on
ice in between.
5. Collect fluid in eppendorf with gel loading tip. Wash 2x with 500 gtl of 1:1
mixture of TCA/TCA buffer collecting the wash in the eppendorf.
6. Centrifuge at top speed for five minutes. Discard the supernatant and be sure the
pellet is dry.
7. Resuspend in pellet in 200 gl resuspension buffer and boil five minutes. You can
aliquot the protein and freeze what you don't use at -70 0 C.
Solutions
20% TCA
20% TCA Buffer
20 mM TrisC1, pH 7.9
50 mM ammonium acetate
2 mM EDTA
TCA Resuspension Buffer
3% SDS
100 mM Tris base, pH 11
3 mM DTT
(store at -20 0 C in 1 mL aliquots)
Andy Rakestraw
May 5, 2006
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Appendix 2.1: Secretion Vectors
Plasmid schematics of secreted BPTI and D 1.3 ligated behind the Gall-10 promoter (not
shown) expressed from the backbone of a pRS3 lx series plasmid. The Gal-gene-
terminator is subcloned into the backbone KpnI to SacI.
EagI 122
NheI 52
pre pro
XhlI 374
BPTI cmyc
Sad 726
Gal4 terminator
pBPTIs
Sad 516
D1.3 scFv
Nhel 107
prepro
pD1.3s
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EagI 831
XhoI 877
mvj
BPTI were both surfaced displayed using an Aga2 fusion protein C-terminal to
The D 1.3 and BPTI surface display schematics and plasmid maps are given
Sad 531
D1.3 scv
MMib 846 XhoI 1094 Sad 1446
cmyc Aga2 I Gal4 terminator I
pD1.3md
NheI 49 EagI 119 Mini 293 XhoI 539
pre pro BPTI I mycAga2 I
pBPTImd
150
Appendix 2.2: Surface Display Vectors
D1.3 and
the gene.
here.
NheI 122
prepro
Appendix 2.3 Doxycycline Titratable Hacl' Vector
The Hacl gene is subcloned into a doxycycline regulatable construct behind the CYC
promoter.
CYC promoter
BamHI 2507 NotI 3261
HI aci
pCYCHacli
151
I
Appendix 2.4 Alpha Mating Factor Prepro scFv Vectors
The 4m5.3 constructs are all built the same. The mutant leaders are subcloned in SphI to
NheI. Note that the FLAG tag is always conserved in the 4m5.3 vector subcloning in this
manner. The D1.3 construct has no FLAG tag but a C-terminal c-myc tag instead. The
sequences for the mutants leaders app8 and appS4 are given at the end of the whole
plasmid maps.
Nhel 293 KpLnI 421
WTapp FLAG
Xhol 1100
4m5.3 scFv
WTapp4m5.3
Nhel 263
WTapp D1.3 scFv
XhoI 1033
NotI 987
EagI 987
WTappD1.3
152
Sphl 6
Sphl 6 I
Appendix 2.5 Alpha Mating Factor Prepro IgG Vectors
The variable light chain from the scFv is subcloned Nhe to BsiWI. The BsiWI site is not
indicated in the plasmid map.
BsiWI
NhelI 293
WTapp VL
XhoI 969
CL
WTapp4mlgGLC
The variable heavy chain from the scFv is subcloned Mlul to NheI
SphI 6 Mhi 263
WTapp
WTapp4mIgGHC
153
Sphl 6
NheI 617
VH
XhoI 1609
CH
Appendix 2.6 PCR Primers
FunctionSequence
Chromosomal Gene Integrations
ggg; "atg rng -ag gggog
goa1a1gtagigt1g -
igaatigoagcga t _N-t ac
crgaaggaaglgagcacagactatg"",g~tg; 'gmg~g,;;'
gglat teacac ;te
-t-I -actaeatggg
Scacagagedcgtacataca
gt cgggttcgtg
galattaaogghttagglagasag
pCYC Haci Construction
CYChacl-1 CAGTGGATCCATGGAAATGACTGATTrTGAACTAAC
CYChac1-2 ATAAGAATGCGGCCGCTCATGAAGTGATGAAGAAATCATTC
Alpha Mating Factor Construction and Mutagenesis
Alpha-pp-f a coatttact
Alpha-pp-r c
AlphaJib.b
AlphaJibf
Seq-pp
wtV22AQCt
wtV22AQCb
S4A22Vqc1
S4A22Vqc2
#8~2Vqc1
#8A22Vqc2
8phobf8phobr
8SSSTf
8SSSTr
8polarf
8polarr
L55FQCf
L55FQCr
F48SQCf
F48SQCr
EagMuQCf
EagMuQCr
Vhmlu2(6-23)
VhXho
VINhe2(6-23)
WXho
Vh4m5.3(mlu)
Vh4m5.3(nhe)
VW4m5.3(nhe)
V14m5.3(Bswl)
Vhseq
agigtoctgagctagagcý
Name
Pura
Pohlong
Ndel
Kohlong
KanU
KanV
Ptrp
Zohlong
Pzohlong
Ztrp
Tchkl
Tchk2
DRT-1
DRT-2
GRT-1
GRT-2
caaggagaaaaocag alpha prepro mutagenesis
~~tcgalaaagt~ta sequencng primer for prepro
Sit-Directed Mutagenesis of Alpha Prepro
CATrAGCTGCCCCAGTCAACACTACAGCAG
CTGCTGTAGTGTTGACTGGGGCAGCTAATG
CATrAGCCGCTCCAGTCAACACCACGACAG
CTGTCGTGGTGrTGACTGGAGCGGCTAATG
cAACAGCACAAATAACTAGGGTTATTGTATAAATACTACTATGCCAG~
TGCTGGCAATAGTAGTATTATAAACAATAACCCGTTATTTGTGCTGTTG
cAACAGCACAAATAACGGGTcATCGTCTACAAATACTACTACTG
CAATAGTAGTA-TTGTAGACGATgACCCGTTA-TTGTGCTGTTG
ccAACAGCACAAATAACGGGTtAgaGgaTgaAAATACTACTATTGCC
GGCAAAGTTAGTATTTtcAtcCIcTaACCCGTATTTGTGCTGTTGG
GCTGCTGCTCTGCCA1-TCCAACAGCAC
GTGCTG1TGGAAAATGGCAGAGCAGCAGC
GATCTAGAAGGGGATtcCGATGCTGCTGCTC
GAGCAGCA GCATCGgaATCCCCTTCTAGATC
IgG Construction
GGGTACAGCTGGATAAAAGAagcgCAGGTGCAGCTGCAGGAGTCTG
CAGACTCCTGCAGCTGCACCTGacgcgtTCTTTTATCCAGCTGTACC
gaGCAACGCGTGTCTTGTCcaggcagaggtgcagtctgag
gaacGCTACGgaggtaciadcagodactc
GAACACGCGTGTCAAACTGGATGAGACTGGAGGAG
GAACGCTAGCGGAGACGGTGACTGAGGTTCCTTG
GAACGCTAGCGACGTCGTTATGACTCAAACACCAC
GAACCGTACGCTTAATMTCAAGCTTGGTGCCTCC
I- tg,;; vtgxm~
A22V site directed mutagenesis (WT)
A22V site directed mutagenesis (WT)
S4 (V22A) site directed mutagenesis
S4 (V22A) site directed mutagenesis
8 (V22A) site directed mutagenesis
9 (V22A) site directed mutagenesis
8 (LSST:LLFI) directed mutagenesis
9 (LSST:LLFI) directed mutagenesis
8 (LSST:SSST) directed mutagenesis
9 (LSST:SSST) directed mutagenesis
8 (LSST:LEDE) directed mutagenesis
9 (LSST:LEDE) directed mutagenesis
8 (L55F) directed mutagenesis
9 (L55F) directed mutagenesis
8 (F48S) directed mutagenesis
9 (F48S) directed mutagenesis
IgG HC Eag to Mu quickchange
IgG HC Eag to Mu quickchange
IgG HC PCR of entire HC (6-23 IgG)
IgG HC PCR of Ch
IgG LC PCR of entire LC (6-23 IgG)
IgG LC PCR of entire LC
PCR of 4m5.3 Vh into IgG
PCR of 4m5.3 Vh into IgG
PCR of 4m5.3 VI into IgG
PCR of 4m5.3 VI into IgG
seq. for HC ligation
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integration into ura3 (gene primer)
integration into ura3 (gene primer)
integration into ura3 (G418R primer)
integration into ura3 (G418R primer)
check ura3 integration
check ura3 integration
integration into trpl (gene primer)
integration into trpl (gene primer)
integration into trpl (ZeoR primer)
integration into trpl (ZeoR primer)
check trpl integration
check trpl integration
check integration copy number (D1.3)
check integration copy number (D1.3)
integration copy number control (GPD)
integration copy number control (GPD)
pCYC Hacl construction
pCYC Haci construction
PCR alpha prepro from gen. DNA
PCR alpha prepro from gen. DNA
alpha prepro mutagenesis
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